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ZUSAMMENFASSUNG 
 
Die Modifikation von Proteinen mit dem Protein SUMO (Small-Ubiquitin-like-Modifier) ist 
wichtig für verschiedenste zelluläre Prozesse wie Transkription, Struktur von Chromatin, DNA 
Reparatur, Abwicklung des Zellzyklus, Signaltransduktion und Nuklearem Transport. Störungen 
dieses Systems wurden in diversen Krankheiten beobachtet wie zum Beispiel unterschiedlichen 
Arten von Krebs und verschiedenen neurodegenerativen Krankheiten. 
Die Konjugation mit SUMO ist ein höchst dynamischer Prozess welcher auf einem ständigen 
Gleichgewicht zwischen Konjugation und Dekonjugation beruht. SUMO Modifikation ist eine 
ATP-abhängige Reaktion, die eine enzymatische Kaskade aus einem E1 aktivierenden Enzym, 
einem E2 konjugierenden Enzym, und einem von wenigen E3 ligierenden Enzymen, benötigt. Die 
meisten - aber nicht alle - Substrate, brauchen die Anwesenheit einer E3 Ligase. Jedoch können 
ein paar Substrate wie zum Beispiel RanGAP1 oderTDG auch ohne Hilfe einer E3 Ligase effizient 
mit SUMO modifiziert werden. 
Das Ziel meiner Arbeit war es weitere E3-unabhängige SUMO Substrate zu finden. Dies wurde 
durch die Durchführung eines in-vitro SUMO Assay auf einem sogenannten ProtoArray™ 
bewerkstelligt. Dieser ProtoArray enthält mehr als 9000 rekombinante humane Proteine. Nach 
Durchführung der in-vitro SUMO Reaktion wurden sumoylierte Proteine mit fluoreszierendem 
Antikörper detektiert. Nach der Analyse wurden einige interessante Substrate ausgewählt, in 
bakterielle Expressionsvektoren kloniert und gereinigt. Mit diesen gereinigten Proteinen wurden 
weitere in-vitro SUMO Reaktionen ausgeführt. 
 
ABSTRACT 
 
Modification with the Small-Ubiquitin-like-Modifier (SUMO) is implemented in diverse cellular 
processes as transcription, chromatin structure, DNA repair, cell cycle progression, signal 
transduction and nuclear transport. Dysfunction in SUMO modification has been observed in 
various diseases including different types of cancer and many neurodegenerative diseases. 
SUMO conjugation (sumoylation) is a highly dynamic event which depends on the equilibrium 
between conjugation and deconjugation. Modification with SUMO is an ATP-dependent reaction 
which is governed by an enzymatic cascade including one E1 activating enzyme, one E2 
conjugating enzyme and most of the time one out of a few E3 ligating enzymes. 
 
Most but not all SUMO substrates depend on the third class of enzymes, the E3 enzymes. Some 
substrates for example RanGAP1 or TDG are efficiently modified without an E3 Ligase in vitro. 
The aim of this work was to identify novel E3 independent SUMO substrates by performing an 
in-vitro SUMO assay on a ProtoArray™. The ProtoArray™ is purchasable as a chip spotted with 
more than 9000 recombinant human proteins. After accomplishing the in-vitro reaction on the 
chip, sumoylated proteins were detected with fluorescently labelled antibodies. After analysis 
some promising substrates were selected, cloned into bacterial expression vectors, purified in 
bacteria and analysed in E3 independent in-vitro SUMO assay. 
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5 Introduction 
 
INTRODUCTION 
 
Ubiquitin and its relatives, the ubiquitin-like proteins (Ubls) are covalently linked to a variety of 
proteins and thereby altering their properties. SUMO, which stands for small ubiquitin-related 
modifier, is one of several ubiquitin-like proteins and the modification system of interest in my 
diploma thesis. 
 
1.1. DISCOVERY  
 
The SUMO gene (SMT3 in yeast) was initially identified in Saccharomyces cerevisiae more than 
15 years ago 1. It became characterized in mammalian cells upon its discovery as binding partner 
for example for the tumour suppressor promyelocytic leukaemia (PML) in a yeast two hybrid 
assay 2. In addition SUMO was found to be covalently attached to the Ran GTPase-activating 
protein (RanGAP1) in mammals and thereby facilitates the interaction with the nucleoporin 
RanBP2 3,4. 
 
Sumoylation is essential for cell viability in budding yeast, nematodes and higher eukaryotes 5. It 
regulates diverse biological processes including transcriptional regulation, nuclear transport, 
apoptosis, cell cycle, signal transduction and the maintenance of genome integrity 6,7,8.  
This large variety of biological consequences can be explained by changes in binding interfaces 
upon covalent attachment of SUMO which results in e.g. changes of intracellular localization, 
stability and/or activity of the modified target protein. SUMO can negatively and positively 
influence protein-protein interactions by either providing a new 9 or interfering with an existing 
binding interface as it is the case for the ubiquitin conjugating enzyme E2-25K 10. Sumoylation 
can also have an important role in assembly of multi-protein complexes as it was shown for PML 
11.  
 
Modification with SUMO is a rapid, dynamic and energetically relative (it also costs ATP) 
inexpensive way to reversibly alter the functions of proteins 5,12. Through sumoylation the 
complexity of the eukaryotic proteome is enormously increased.   
SUMO modification seems to alter the long-term fate of the substrates, even though the SUMO 
conjugation may be rapidly deconjugated 8. SUMO conjugation depends on the equilibrium 
between conjugation and deconjugation 12. Although only a small fraction of the target proteins 
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are modified with SUMO at a given time, this small proportion could be enough to affect a 
change in the physiological state 9. 
 
1.2. THE SUMO FAMILY 
 
SUMO belongs to a highly conserved protein family. SUMO proteins are ~11kD in size; due to the 
long flexible N-terminus they add approximately 15 to 20kDa to the molecular weight of its 
substrates in SDS-PAGE. SUMO resembles the three-dimensional structure of ubiquitin (Figure 
1), but share only less than 20% of the amino-acid sequence with ubiquitin 1,13. 
 
SUMO proteins are ubiquitously expressed throughout all eukaryotes. Some organisms such as 
yeast, Caenorhabditis elegans and Drosophila melanogaster possess a single SUMO gene 
whereas other organisms such as vertebrates and plants have several SUMO genes 6. 
Arabidopsis thaliana even contains eight SUMO genes 14,15. In humans four distinct SUMO 
proteins are encoded in the genome: SUMO1 to SUMO4 5,6. SUMO1 (also known as GMP-1, PIC1, 
Sentrin, Ubl1, Smt3c and hSmt3) to SUMO3 are ubiquitously expressed, however, SUMO4 is 
thought to be expressed mainly in the kidney, lymph node and spleen16,17. 
 
SUMO has distinct positive and negative surface charge distributions. SUMO proteins have an 
unstructured stretch of 10-25 amino acids at their N termini. The N-terminal extension is flexible 
in solution and can be completely deleted in yeast without severe effects in vegetatively growing 
cells 18. The three dimensional signal of the C-terminal core structure of SUMO presents the 
typical β-grasp fold shared by the different Ubiquitin-like modifiers 9 (Figure 1).  
 
Figure 1  Structual alignment of the backbones of SUMO1 (in pink) and Ubiquitin (in blue) from Protein Modification by SUMO by 
Erica Johnson 2004. The N-Termini are on the left and SUMO1 possess here an unstructured stretch. C-Termini are on the right. 
 
In cells SUMO is expressed as an inactive precursor carrying a C-terminal stretch with variable 
length (2-11 amino acids) downstream of the invariant Gly-Gly motif. To activate the protein this 
C-terminal extension has to be removed by SUMO-specific proteases to free the Gly-Gly motif 
which is essential for target modification 13.  
 
7 Introduction 
The mature forms of SUMO2 and SUMO3 are almost identical whereas SUMO1 shares only 50% 
sequence identity with the SUMO2/3. SUMO1 and SUMO2/3 were shown to have distinct but 
overlapping functions 1. This is supported by the surprising finding that disruption of SUMO1 in 
mice is not lethal most likely because SUMO2/3 can compensate for its function 19.   
Cells contain large pools of free unconjugated SUMO2/3; however there is virtually no free pool 
of SUMO-1, at any given time. This suggests that the majority of SUMO1 is constitutively 
conjugated to its substrates 20,21, whereas SUMO2/3 gets conjugated upon different stress 
stimuli 22.  
Many SUMO substrates are sumoylated at one or multiple sites with a single SUMO (mono-
SUMO) although poly SUMO chain formation is described mainly for SUMO2/3 targets upon 
different stress stimuli 23. 
 
1.3. MECHANISM OF SUMO CONJUGATION AND DECONJUGATION 
 
SUMO entities are conjugated to their target proteins via a three step enzyme pathway. These 
enzymes are specific for SUMO modification. SUMO modification knows one E1, one E2 and 
several E3 enzymes 24,25,26,27,28,29 (Figure 2). 
Sumoylation results in the formation of an isopeptide bond between the C-terminal Gly residue 
of the modifier protein (SUMO) and the ε-amino group of a Lysine residue in the substrate. 
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Figure 2   SUMO Modification Cycle: SUMO is activated in an ATP dependent reaction resulting in SUMO~AMP and releasing 
pyrophosphate. The E1 enzyme attacks the activated SUMO protein with its active cysteine, which results in the formation of a 
thioester bond between the E1 enzyme and SUMO. In the next step SUMO is transferred to the E2 enzyme and they are also 
connected via a thioester bond. In the final step, SUMO is transferred to the substrate and an isopeptide bond is formed. This step is 
usually facilitated by E3 ligases. The process of sumoylation is reversible and is performed by several isopeptidases. 
1.3.1. SUMO-ACTIVATING ENZYME E1 
First, the mature SUMO needs to be activated at its C-terminal Gly-Gly by the SUMO- specific 
activating enzyme E1. The E1 is a heterodimer consisting of Aos1 (also called SAE1) and Uba2 (or 
SAE2). Aos1 resembles the N-terminus of the ubiquitin activating enzyme E1 and Uba2 
corresponds to the C-terminus that contains the active cysteine 30.  
Formation of a SUMO- adenylate requires ATP. SUMO attacks ATP with its C-terminal carboxyl 
group, this results in a SUMO C-terminal adenylate and pyrophosphate is released. The thiol 
group of the active cysteine in the E1 attacks the SUMO adenylate. It thereby releases AMP and 
forms a high-energy thioester bond between the E1 and the C-terminus of SUMO 5,31.  
1.3.2. SUMO-CONJUGATING ENZYME E2 
The E2 conjugating enzyme Ubc9 accepts SUMO from the E1 enzyme and subsequently catalyses 
the transfer to the substrate by selecting the target Lysine for modification. Ubc9 is the only 
known SUMO-conjugating enzyme in yeast and invertebrates and most likely in vertebrates as 
well 25,26. This is supported by the findings that the Ubc9 gene is essential in all tested organisms 
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32,33,34 except in fission yeast where it is not crucial 35,36. Interestingly, in the ubiquitin pathway 
multiple E2 enzymes are involved in ubiquitin conjugation and play roles in different cellular 
pathways 37.  
 
Upon accepting SUMO from the E1 enzyme a thioester bond between the catalytic Cysteine 
residue of Ubc9 and the C-terminal carboxy group of SUMO is formed. Since this bond is highly 
reactive it serves as a donor for the final reaction where SUMO is transferred to the substrate. 
This results in the formation of a stable isopeptide bond between the C-terminal Glycine residue 
of SUMO and a Lysine side chain of the substrate 5,8.  
 
Ubc9 has a strong overall positive charge and its three dimensional structure strongly resembles 
ubiquitin E2 enzymes 38. The patch around Ubc9´s active Cysteine directly recognizes SUMO 
consensus sequences often found in SUMO substrates 39 (discussed in section 1.3.5). However, 
additional residues in Ubc9 might have a role in correctly orienting the thioester linked SUMO 
and/or stabilizing the substrate interaction to facilitate isopeptide bond formation 39,40. The 
residues of Ubc9 which are in direct contact with the substrate Lysine seem to have a role in 
catalysis rather than in substrate binding 41. 
 
Nevertheless, the interaction of the SUMO consensus site with the catalytic cleft in Ubc9 is 
usually not sufficient for efficient SUMO transfer. Therefore most targets depends on E3 ligases 
for efficient modification 42. 
1.3.3. E3 SUMO LIGASES  
SUMO E3 ligases catalyse the transfer of SUMO from Ubc9 to a substrate promoting the 
sumoylation efficiency. E3 ligases are involved in most sumoylation events in vivo. The E2 
contributes to target recognition, but the E3 ligases usually confer substrate specificity and 
accelerate catalysis 42. 
The classical definition of an E3 enzyme is that it binds the E2 and the substrate thereby 
promoting the transfer of SUMO from the E2 to the target. None of the known SUMO E3s form 
covalent intermediates with SUMO; however they bring together Ubc9 and the substrate. 
Selected SUMO E3 ligases seem not to interact directly with the substrate and rather stabilize 
and orient the SUMO charged E2 for optimal transfer 40. However, no direct role of E3s in lysine 
activation during SUMO conjugation has been demonstrated. This suggests that the catalytic 
potential which is required for conjugation comes from the E2. 41 
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SUMO conjugation can take place in vitro in the absence of an E3, at the Lysine residues that are 
actually modified in vivo 24. However, the majority of substrates depend on E3 ligases for 
efficient sumoylation 43. RanGAP1 is the prime example which seems not to require an E3 ligase 
for efficient modification. Interestingly, the RanGAP1-Ubc9 binding is stabilized through an 
additional  binding interface and indeed this interaction is required for its efficient 
sumoylation.39 
Four different types of E3s have been identified in the last years which includes the largest 
group, the SP-RING family (contains the Siz/PIAS family members)43, the nucleoporin RanBP2 29, 
the polycomb group protein 2 44 and TOPORS 45. Several of these proteins resemble ubiquitin E3 
ligases and are regulated by posttranslational modifications for example phosphorylation and/or 
S-nitrosylation 46,47,48,49.  
1.3.4. SUMO PROTEASES  
Sumoylation is a reversible modification and one class of enzymes able to cleave SUMO are 
described 50. All known SUMO cleaving enzymes, called isopeptidases, belong to a class of 
Cysteine proteases with a ~200 amino acid conserved C-terminal domain 51. In humans they are 
called sentrin-specific proteases (SENPs). They have three main functions: they remove SUMO 
from its substrates (isopeptidase cleavage), thereby making the modification reversible, they are 
responsible for the pool of matured SUMO in the cell (SUMO processing) 5, and they edit SUMO 
chains 52.  
1.3.5. THE SUMO CONSENSUS SITE 
Many of the substrates share a common motif for modification, a so called SUMO consensus 
site: ΨKxE where Ψ is a bulky hydrophobic amino acid (Isoleucine, Leucine or Valine), K is the 
Lysine which is conjugated to SUMO, x is any amino acid and E is Glutamic acid. The SUMO 
acceptor site was identified after mapping Lysine residues in the SUMO targets/substrates 
RanGAP1 53, PML 54, Sp100 55 and p53 56. The catalytic cleft of Ubc9 directly recognizes this 
tetrapeptide (ΨKxE) on the target 39. Hence Ubc9 is not only capable of catalysing the transfer of 
the SUMO protein to the substrate but also selects the accurate lysine residue for modification 
57. 
 
Sumoylation often occurs on a SUMO consensus motif but far not all SUMO consensus motifs 
are de facto modified. One example is E2-25K which has three SUMO consensus motifs but is 
modified at a non-consensus Lysine. Other SUMO substrates like DAXX do not even contain a 
SUMO consensus site.  
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Structural studies have shown that a SUMO consensus motif can only be recognized by Ubc9 if it 
is in an unstructured area or part of an extended loop, as in RanGAP1 39 but not when located in 
an  -helix as in E2-25K 10. Due to this direct interaction of Ubc9 with the SUMO consensus site 
in its targets it is not surprising that E1 and Ubc9 are often sufficient to sumoylate many 
substrates at the correct sites in vitro also in the absence of an E3 24. 
 
Some SUMO substrates show enhanced sumoylation due additional Ubc9 binding sites in close 
proximity to the classical SUMO consensus motif. Two different extensions to the SUMO-
consensus motif are described. 
The phosphorylation-dependent sumoylation motif (PDSM). It is found in heat shock factor-1 
(HSF1), myocyte enhancer factor 2 (MEF2) and several other proteins 58. This motif consists of 
the conventional sumoylation motif followed by a phosphorylated Serine and Proline residue 
(ΨKxExxpSP). Phosphorylation is required for sumoylation of HSF1 and MEF2A in vivo 59. 
The additional negative charge of the phosphate group might enhance substrate binding to the  
basic surface of Ubc9 and thus promotes SUMO conjugation (MEF2 and HSF1) 60. 
Phosphorylation dependent sumoylation provides an additional level of regulation.  
 
A second extended SUMO motif was identified: the negatively charged amino-acid-dependent 
sumoylation motif (NDSM)61. The negatively charged residues at position +3 in the NDSM were 
found to directly interact with the two positively charged residues (Ubc9 K59 and K61) and this 
interaction is important for modification. Again an additional binding interface between the 
substrate and Ubc9 is created61. 
 
The PDSM motif is more common than the NDSM and the main difference between these motifs 
is that NDSM is constitutive whereas the PDSM is regulated via its phosphorylation 62.  
1.3.6. THE SUMO INTERACTING MOTIF 
SUMO does not only bind proteins by covalent interactions also non-covalent interactions are 
described mediated via a SUMO-Interaction Motif (SIM) 63,64,65.  
A SIM consists of a short hydrophobic core which is often flanked by acidic and/or Serine 
residues 66. The consensus sequence for the hydrophobic core is identified as Val/Ile-X-Val/Ile-
Val/Ile (V/I-X-V/I-V/I). This motif can bind SUMO either in a parallel or anti-parallel orientation 67. 
The acidic residues at the ends of the SIM interact with the basic residues on the SUMO surface 
9, whereas the Serine residues might regulate SUMO binding by phosphorylation, because the 
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negative charge would strengthen SUMO binding. However, the importance of the Serine 
residues has been questioned in another study 68.  
 
SIMs have been identified in a wide range of proteins including SUMO substrates, SUMO 
enzymes and SUMO binding proteins with functions in many cellular processes including DNA 
repair, transcriptional activation, nuclear body formation and protein turnover. Here a few 
examples are presented. 
SIMs can function as prerequisite for efficient modification. SIM containing SUMO substrates like 
the base excision repair enzyme thymine DNA glycosylase (TDG), the transcription factor DAXX 
and the ubiquitin specific protease Usp25 depend on a functional SIM motif for efficient SUMO 
conjugation 69. This suggests that the SIM helps to recruit and/or positions the Ubc9~SUMO 
thioester for efficient conjugation.  
In case of TDG the SIM also contributes to its conformational changes. TDG binds and hydrolyses 
mismatched Thymine and Uracil bases and remains tightly bound to abasic sites. Sumoylation of 
TDG and the subsequent intramolecular SIM interaction leads to a conformational change which 
releases TDG from DNA70. 
The most common function of SIM containing proteins is to establish interactions with SUMO 
conjugated proteins. One example is represented by the SUMO targeted ubiquitin E3 ligase 
RNF4 that recognizes polysumoylated substrates with its four SIMs 71,72. 
Another prominent example is PML which is a SUMO substrate but also contains SIMs that non-
covalently interact with SUMO. PML sumoylation is a prerequisite for nuclear PML body 
formation and it is thought that sumoylated PML functions as a molecular scaffold to recruit its 
binding proteins via covalent and non-covalent SUMO interactions 11. 
 
Several SUMO substrates including proteins which are important for transcription, DNA repair 
and chromatin remodelling were found to have SIMs including e.g. Sp100, PML, TDG, Daxx, and 
all SUMO E3 ligases 65,73. 
 
The identified functions of SIMs are very diverse as they can be important for substrate 
modification, conformational changes and interation with specific binding partners. 
In the case of TDG the SIM is not only required for efficient SUMO modification by recruiting or 
positioning the Ubc9~SUMO thioester 42, it is also involved in the intramolecular interaction with 
the SUMO covalently attached to TDG leading to a conformational change 74,70. A prominent 
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example for the involvement of SIMs in recruitment of binding partners is PML body formation 
75,76. 
 
SIMs were found to be regulated by phosphorylation which is performed by the 
Serine/Threonine Kinase CK2. This phospho-regulated SIM module was found in the E3 ligase 
PIAS1, in PML and in PMSCL1. The phosphor-dependent SUMO does not impair the ligase activity 
but affects the transcriptional coregulatory role of PIAS1 77. 
 
Ubc9 itself has no classical SIM but also interacts noncovalently with SUMO in a SIM 
independent manner. It was shown that SUMO interacts far from the E2 active site, with the N-
terminal helix, the first β-strand and the intervening loop of Ubc9 78. 
 
1.4. CONSEQUENCES OF SUMOYLATION 
 
Sumoylation can influence diverse aspects of a target protein including stability, intracellular 
localization and/or activity. This large variety of consequences can be explained by the fact that 
conjugation with SUMO locally alters the surfaces of its substrates and therefore it can interfere 
with existing /or provide novel intra- and extramolecular binding interfaces. 
 
Sumoylation creates novel extramolecular binding interfaces 
One prime example comes from studies with RanGAP1. Unmodified RanGAP1 is soluble in the 
cytosol. Upon sumoylation RanGAP1 changes its cellular localization by recruiting it to the outer 
nuclear membrane where it interacts with the nucleoporin RanBP2 4,39. 
 
As already mentioned above PML has a prime function in nuclear body formation: Promyelotic 
leukaemia nuclear bodies are dynamic intranuclear structures which lack a membrane. They are 
regulated in response to genomic stress and during the cell cycle and possess crucial tumor-
suppressive functions 76. PML acts as the structural scaffold of these nuclear bodies and is able 
to recruit other proteins which are important for transcription and DNA-damage response 76. 
PML is a SUMO substrate with several SIMs and this provides binding interfaces for both 
sumoylated substrates and SIM containing proteins 75. Several PML binding proteins are SIM 
containing SUMO substrates including DAXX, TDG and Sp100 65.  
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The polymerase processing factor PCNA is a SUMO substrate which recruits upon sumoylation 
the yeast DNA helicase Srs2 during S phase to replication forks to prevent DNA recombination 
79,80. PCNA functions as a messenger platform for different polymerases due to its 
posttranslational modifications 81. 
 
Sumoylation  interferes with an existing binding interface 
The ubiquitin-conjugating enzyme E2-25K is sumoylated at its first N-terminal alpha helix, an 
established binding interface for the ubiquitin E1 enzyme. E2-25K sumoylation impairs its activity 
in forming ubiquitin thioesters and unanchored ubiquitin chains by interfering with E1 
interaction 10.  
 
Sumoylation dependent conformational changes via intramolecular interactions 
As mentioned earlier the Thymine DNA Glycosylase is a DNA repair enzyme and an enzyme that 
removes mismatched thymine and uracil bases by binding and hydrolysing the mismatched base. 
TDG then remains tightly bound to the abasic site 82. Sumoylation of TDG is the important switch 
that triggers a conformational change in TDG 70. Therein residues which are required for SUMO 
modification as well as the residues in the SIM are required to induce the conformational change 
in TDG. A protruding helix in the protein structure of sumoylated TDG interferes sterically with 
DNA binding 83. This results in decreased affinity of TDG for DNA and TDG can be releases from 
the DNA and the subsequent repair of the abasic site can be further promoted. 
 
1.5. REGULATION OF SUMOYLATION 
 
Sumoylation is regulated at diverse levels including the individual substrates, SUMO and its 
enzymes for conjugation and deconjugation. 
 
Many SUMO substrates are targets for different posttranslational modifications such as 
acetylation, methylation, phosphorylation and ubiquitination. These modifications can regulate 
SUMO conjugation in different ways. 
Phosphorylation for example can either enhance substrate sumoylation by increasing its affinity 
for the E2 or the E3 enzyme 60 but also negatively regulate sumoylation by interfering with the 
SUMO conjugation enzymes as it is described for p53 84. In case of IKBα sumoylation protects 
from proteasomal degradation as ubiquitin and SUMO compete for the same acceptor Lysine 85. 
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The opposite is true for other substrates in which sumoylation is a prerequisite for ubiquitination 
and proteasomal degradations (eg. PML etc). 
Also the intracellular localization can determine the sumoylation status of a protein as it was 
found for Sp100 which needs to be recruited to the nucleus for modification 86. 
 
SUMO itself seems to be regulated at different levels. SUMO1-3 are ubiquitously expressed, but 
there are variations in different tissues 87. SUMO1 expression was shown to be increased in 
response to hypoxia 88. Additionally, SUMO1 itself can be a target for posttranslational 
modifications like acetylation and phosphorylation 89,90. 
 
Influencing the regulation of the E1 enzyme has a huge impact on global sumoylation 12. The 
protein Gam1 of the CELO virus induces proteasomal degradation of SUMO E1 enzyme 91. During 
oxidative stress, low H2O2 levels induce reversible disulphide bond formation between the 
catalytic Cysteines of the E1 subunit Uba2 and Ubc9. This results in desumolation of most 
cellular SUMO substrates 92. 
 
Ubc9 is the only known SUMO E2 enzyme. Ubc9 can get modified by S-nitrosylation after 
treatment with the nitric oxide donor GSNO 46. Additional mechanisms of Ubc9 regulation will be 
discussed in the next section. 
 
SUMO E3 ligases can also be regulated by posttranslational modifications. As for example 
phosphorylation of Topors negatively influences its E3 function 48.The opposite was shown for 
the polycomb group E3 ligase Pc2 which is activated upon phosphorylation 47. S-nitrosylation 
negatively influences the E3 ligase Pias3 by marking it for ubiquitin dependent degradation 46. 
 
SUMO proteases seem to be regulated at the transcriptional level since they are differentially 
expressed in different tissues 87. 
The regulated intracellular localization of substrates, E3 enzymes and SUMO proteases 
determines the sumoylation status of a substrate and the activity of the enzymes, respectively 
52,55,93,94,95,96,97,98,99,100,101.  
1.5.1. UBC9 FUNCTION AND REGULATION  
Ubc9 was found to be highly upregulated in many types of different human cancer including lung 
adenocarcinoma 102,103, melanoma104, prostate cancer 105, breast cancer 106,107 and a specific form 
of acute myeloid leukemia (AML) 108. In addition sumoylation is implicated in the pathogenesis of 
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type 1 diabetes 109. In summary these findings indicate that Ubc9 overexpression may be 
involved in the pathogenesis of different diseases and therefore might be an attractive target for 
drug development110. Due to the fact that Ubc9 dependent sumoylation is involved in diverse 
cellular processes as cell cycle regulation 26, DNA repair 111 and apoptosis 112,113, alterations in 
sumoylation could have a major impact on cell homeostasis. However, the molecular mechanism 
of how Ubc9 would mediate pathogenesis remains elusive since most SUMO substrates are 
expected to be regulated by E3 ligases and would be restricted to their regulation.  
 
Beside upregulation different other mechanism regulating Ubc9 were described including 
nitrosylation, oxidation and sumoylation 46,92,114. While oxidation reversibly inactivates Ubc9 the 
consequences of its nitrosylation are unknown 46. 
Our lab recently analysed the consequences of Ubc9 sumoylation. Ubc9 is sumoylated at Lysine 
14 in mammalian cells (S*Ubc9) 42. Detailed biochemical analysis indicates that this modification 
does not significantly impair its catalytic activity and in this line sumoylation of most substrates 
including HDAC4, E2-25K, PML or TDG is unaffected 42. However, turning to two other well 
known SUMO substrates: RanGAP1 and Sp100 led to different scenarios: In the presence of 
S*Ubc9 RanGAP1 sumoylation is significantly impaired whereas Sp100 modification is strongly 
enhanced as otherwise only obtained in the presence of an E3 ligase. This enhancement 
depends on the non covalent interaction via a SIM motif in Sp100 which recognizes the SUMO 
conjugated to Ubc9. Interestingly, other SIM containing SUMO substrates (Daxx, PML and TDG) 
show only minor or no increase with S*Ubc9. Structural analyses of S*Ubc9 indicates that SUMO 
binds to a hairpin loop in Ubc9 and is therefore forced in a specific orientation. This finding 
suggests the requirement of a defined distance between the SIM and the site of modification in 
the substrate 42. 
 
In our current working model Ubc9 itself significantly contributes to target selection at least for 
selected SUMO substrates (Figure 3):  
In all known sumoylation events SUMO is directly transferred from the charged Ubc9 to the 
substrate. The catalytic cleft of Ubc9 directly interacts with a SUMO concensus motif in the 
substrate but usually this interaction is not sufficient for efficient modification. RING type E3 
ligases recognize both the charged E2 and the substrates which lead to an increase in affinity 
and an enhanced SUMO transfer to the substrate. Alternativly different E3 independent 
mechanisms are described: RanGAP1 is very efficiently modified in the absence of an E3 ligase 
and this depends on an additional binding interface with Ubc9 39. Additional Ubc9 binding can 
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also be achieved by a negatively charged binding interface as it is shown for Elk-1 61. Two other 
mechanisms involving non covalent SUMO binding via SIMs are described: In one scenario the 
SIM containing substrate positions the SUMO thioester loaded Ubc9 115,116; in another scenario 
recruitment is via the sumoylated (isopeptide linked) Ubc9 42. 
 
Figure 3  Model of Ubc9´s role in target discrimination via different modes of increasing substrate affinity. Ubc9`s catalytic cleft 
directly recognizes a SUMO consensus motif in the substrate. For efficient modification this interaction is not sufficient and depends 
on additional binding interfaces which can be E3 dependent (left panel) or E3 independent (right panel). Classical E3 ligases bind 
both the substrate and the E2 enzyme to bring them in close proximity for efficient modification. E3 independent interactions involve 
additional binding interfaces with either Ubc9´s surface (e.g. RanGAP1) or a covalently Ubc9-linked SUMO (Ubc9 thioester linked 
SUMO: Daxx, TDG, BML, Usp25 or isopeptide linked sumoylated Ubc9: Sp100) and a SIM in the substrate. Model adapted from Ubc9 
Sumoylation regulates target discrimination by Knipscheer et al. 
 
In conclusion different substrates interact via diverse surfaces directly or indirectly with Ubc9 
aside from the consensus motif interaction with Ubc9´s catalytic cleft. These additional binding 
interfaces (E3 dependent and independent) enhance the affinity to the substrate leading to an 
increase in modification. Together these findings indicate that Ubc9 regulation significantly 
contributes to substrate selection and its deregulation (e.g. Ubc9 overexpression) may be a key 
event in disease onset. To clarify the role of Ubc9 deregulation additional substrates directly 
regulated by Ubc9 need to be discovered. 
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1.6. AIM OF MY THESIS 
 
Although most SUMO substrates require E3 ligating enzymes for efficient modification, selected 
targets like RanGAP1 are efficiently modified without this class of enzymes. RanGAP1 stably 
interacts with Ubc9 via two binding interfaces: one involves the SUMO consensus site in 
RanGAP1 and the catalytic cleft in Ubc9 which is common for many SUMO substrates; the 
second binding interface seems to be specific for RanGAP1 and is not described for other 
substrates. This interface is required for stable interaction with Ubc9 and for efficient 
modification. Interestingly also some other substrates developed mechanisms to increase their 
affinity to Ubc9 leading to enhanced modification. In my thesis I was interested to learn about 
the generality of E3 independent sumoylation which may help to explain how Ubc9 
overexpression, frequently found in cancer, contributes to disease onset and/or pathogenesis.  
 
To achieve this goal I have established conditions to perform an E3 independent in vitro 
sumoylation reaction on a human ProtoArray™ from Invitrogen. This array contains more than 
9000 recombinant human proteins, purified from insect cells and spotted on specially coated 
glass slides. Such an array was recently established for the identification of specific substrates 
for ubiquitin E3 ligases 117,118,119. To perform an in vitro sumoylation reaction on this array the 
purification of bacterially expressed HA-tagged SUMO1, the heterodimeric SUMO E1 enzyme 
and the E2 enzyme Ubc9 was required. Prior to applying these enzymes to the array, known 
SUMO substrates were tested, to identify ideal conditions for the discovery of E3 independent 
substrates. Finally, initial analysis of two identified proteins was performed.   
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RESULTS 
 
2. PURIFICATION OF SUMO AND ITS E1 AND E2 ENZYMES  
 
An E3 independent in vitro sumoylation assay requires SUMO and its E1 and E2 enzymes as 
recombinant proteins expressed and purified from bacteria. Subsequently the optimal 
conditions have to be identified by comparing sumoylation of known SUMO substrates.  
 
2.1. PURIFICATION OF THE SUMO ENZYME E1 
The SUMO E1 enzyme is a heterodimer between Aos1 and Uba2. Aos1 has a molecular mass of 
approximately 40 kDa and Uba2 of approximately 90 kDa. Both subunits were cloned under the 
IPTG inducible T7 promotor as His tagged versions.  While Aos1 was N-terminally tagged, Uba2 
was tagged at its C-terminus. The proteins were individually expressed and purified following 
standard protocols. Subsequently, both components were mixed to form the catalytic active 
heterodimer which was separated from the single components by gel filtration. 
 
Purification of His-Aos1 
In brief, the His-Aos1 containing plasmid was transformed in the bacterial strain E. coli BL21 gold 
and expression was induced upon addition of 1 mM IPTG for 6 hours at 25 °C. Bacterial lysis was 
by shock freezing in liquid nitrogen prior addition of Lysosyme. His-tagged proteins were 
enriched on Ni2+-beads (Invitrogen) and elution was with high concentrations of imidazol which 
releases the tagged proteins from the beads. Protein containing fractions were pooled, 
concentrated and further purified by size exclusion chromatography on a gelfiltration column 
using an ÄKTA FPLC system.  
Figure 4-A shows the chromatogram of His-Aos1. On the x-axis the elution volume is plotted in 
fractions collected and the y-axis demonstrates the protein concentration in mAU (milli 
absorbence unit) which are measured by light absorbance of aromatic amino acids (Tryptophan, 
Tyrosin and Phenylalanin) at 280nm. The conductivity of the buffer is measured in 
millisiemens/cm (mS/cm) and determines the salt concentration. His-Aos1 elutes from the 
column as broad peak with a sholder. 10 µl of every other peak fraction, together with aliquots 
of uninduced and induced His-Aos1 transformed cells, were separated on a 5-20% SDS PAGE 
(Figure 4-B). Protein was stained with Coomassie brilliant blue. Indeed, strong induction of His-
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Aos1 migrating at approximately 40kDa was obtained upon IPTG induction. Elution of His-Aos1 
peaked at fractions 7 to 17 (5.5 ml) were pooled for further usage.  
 
 
 
 
Figure 4.  Purification of recombinant His-Aos1. His-Aos1 expression was IPTG induced in E. coli BL21 gold, enriched on Ni2+ beads 
prior separation by size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram of His-Aos1 on a S200 
gelfiltration column. The x-axis represents the eluted volume in sample fractions (0,5ml) and the y-axis the protein concentration in 
mAU (milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity in mS/cm. (B) Immunoblot analyisis of 
uninduced (-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) were separated on a 5-20% SDS-PAGE. Protein was 
stained with Coomassie brilliant blue. Fractions 7 to 17 were pooled and used for E1 complex formation. 
 
Purification of Uba2-His 
Next, Uba2 which is C-terminally tagged with His-(Uba2-His) was purified following the same 
procedure. Figure 5-A shows the monitored size exclusion gelfiltration elution chromatogram. 
Uba2-His eluated in one major peak with several small shoulders. Again protein containing 
fractions were analysed on SDS-PAGE together with aliquots of uninduced and induced bacteria 
A 
B 
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samples. As shown is Figure 5-B Uba2-His migrates at 90 kDa. Since all fractions contained fair 
amout of Uba2 they were all pooled and used for E1 complex formation. 
 
 
 
Figure 5  Purification of recombinant His-Uba2. His-Uba2 expression was IPTG induced in E.coli BL21 gold, enriched on Ni2+ beads 
prior separation by size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram of His-Uba2 on a S200 
gelfiltration column. The x-axis represents the eluted volume in sample fractions (0,5ml) and the y-axis the protein concentration in 
mAU (milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity in mS/cm. (B) Immunoblot analyisis of 
uninduced (-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) were separated on a 5-20% SDS-PAGE . Protein was 
stained with Coomassie brilliant blue. Fractions 9 to 16 were pooled and used for E1 complex formation. 
 
E1 complex formation 
For forming an acive E1 complex, comparable molar amounts of His-Aos1 and Uba2-His have to 
be used. Therefore the concentrations of both purified proteins were estimated on a gradient 
gel (Figure 6-A) to use by a dilution series. Samples were separated on an SDS PAGE and stained 
with Coomassie brilliant blue. As demonstrated in Figure 6-A His-Aos1 was approximately twice 
as concentrated as Uba2-His and therefore they were mixed in a 1:2 ratio to obtain equimolar 
amounts for complex formation. After one hour incubation on ice the reaction was subjected to 
A 
B 
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size exclusion chromatography to separate the complex from its single components. The elution 
chromatogram is shown in Figure 6-B and demonstrates three peaks. The first and largest peak 
corresponds to the complex, the second represents Uba2-His and the third the smallest 
component His-Aos1. Fractions of the first peak were separated on SDS-PAGE and proteins were 
stained with Comassie brilliant blue as depicted in Figure 6-C. Fractions containing equimolar 
amounts of His-Aos1 and Uba2-His (35-37) were pooled and concentration was measured by 
comparison to defined concentrations of a mixture of two reference proteins, Ovalbumine 
(44.3kDa) and Phosphorylase (97.2.kDa) (Figure 6-D). The concentration of the purified E1 was 
estimated to 0.5 µg/µl.  
 
 
 
A 
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Figure 6  E1 complex formation. (A) Identification of equivalent molar concentrations of purified His-Aos1 and His-Uba2. Protein 
amounts of 2, 1, 0.5, 0.25 and 0.12 µl were determined on a 5-20% SDS PAG, stained with Coomassie brilliant blue. (B) Elution 
chromatogram of the E1 complex on a S200 gelfiltration column. The x-axis represents the eluted volume in sample fractions (0,5ml) 
and the y-axis the protein concentration in mAU (milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity 
in mS/cm. (C) Immunoblot analyisis of eluted peak fractions from (B) were separated on a 5-20% SDS-PAGE. Protein was stained with 
Coomassie brilliant blue.. (D) Concentration determination of the E1 complex with two reference proteins Ovalbumine and 
Phosphorylase. E1 protein concentration of 2, 1, 0.5, 0.25 and 0.12 µl was compared to 2, 1, 0.5, 0.25 and 0.12 µg 
Ovalbumine/Phosphorylase. The concentration was determined as 0.5 µg/µl. 
 
2.2. PURIFICATION OF THE SUMO E2 ENZYME UBC9 
The sole SUMO E2 enzyme Ubc9 has a molecular mass of 18 kDa and was purified as untagged 
protein. It was cloned into the pET23a vector were its expression is driven by the T7 promotor. 
The plasmid was transformed into E. coli strain BL21 gold and induction was with 1 mM IPTG for 
4 hours at 37°C. Because of its small size Ubc9 easily leaks out by lysing the bacteria in a 
freeze/thaw step and no further Lysozmye treatment is required. The Ubc9 containing 
supernatant was incubated with SP Sepharose beads (GE Healthcare) which are strong cation 
exchangers and efficiently bind to the positively charged Ubc9 by incubation for 1.5 hours at 4°C. 
After extensive washing steps, Ubc9 was eluted in 1ml fractions with high salt concentration 
(300 mM NaCl). Protein containing fractions, determined by spotting on a nitrocellulose 
C 
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membrane and staining with Ponceau, were collected and pooled. Next, the pooled sample was 
applied to size exclusion chromatiography on a FPLC Äkta system. Ubc9 eluated in one clean 
peak as monitored via a protein density profile shown in Figure 7-A. Peak fractions were 
analysed on a 12.5% SDS PAGE and protein was stained with Coomassie brilliant blue (Figure 7-
B). Fraktion 50 to 54 contained highly concentrated Ubc9 and were pooled before determining 
the protein concentration in comparison to defined concentrations of Trypsin Inhibitor (20.1 
kDa) (Figure 7-C ). The estimated concentration of Ubc9 was 2 µg/µl. 
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Figure 7 Purification of recombinant Ubc9. Ubc9 expression was induced by IPTG in BL21 gold. Purification involved binding to SP 
Sepharose and separation on size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram indicated a single 
peak containing recombinant Ubc9. (B) Aliquotes of uninduced (-IPTG) and induced (+IPTG) bacteria cells, extracts before (bSP) and 
after (aSP) incubation with SP beades, sample injected to gelfiltration (Load) and eluted peak fractions from (A) were separated on 
15% SDS PAGE and protein was stained with Coomassie brilliant blue. Fractions 50 to 54 were pooled and used for further usage. (C) 
Determination of the protein concentration by comparison to the reference protein Trypsin Inhibitor. Ubc9 concetration in 2, 1, 0.5, 
0.25 and 0.12 µl was compared to 2, 1, 0.5, 0.25 and 0.12 µg of Trypsin Inhibitor. Concentration was determined as 2 µg/µl. 
 
2.3. PURIFICATION OF SUMO1 PROTEIN 
SUMO1 with a predicted size of 11kDa was cloned in its active form (SUMO1ΔC4) in pET11a 
under the control of the T7 promoter. IPTG induced expression in E.coli BL21 gold was at 37 °C 
for 4 hours. The cells were lysed by a freeze and thaw cycle followed by sonification. SUMO1 has 
a negative charge and can therefore be bound to the strong anion exchange matrix of Q 
Sepharose (GE Healthcare). The bound SUMO protein was eluted with high salt concentration 
(500 mM NaCl). Protein containing fractions were identified by spotting small aliquots of each 
fraction on a nitrocellulose membrane and staining with Ponceau.  
The peak fractions were pooled and separated on a size exclusion chromatography using an 
ÄKTA FPLC system. Protein elution in 5 ml fractions was monitored via a protein density 
chromatogram as depicted in Figure 8-A. The elution profile shows three peaks of which the 
middle peak represents SUMO1 as it was determinded by earlier purifications. Fraction 33 to 38 
of this peak were analysed on a 12.5% SDS-PAGE (Figure 8-B) followed by Coomassie brilliant 
blue staining. Importantly, in SDS-PAGE SUMO1 migrates at approximately 20 kDa because of its 
long flexible N-terminus. Fractions 33 to 37 containig highly concentrated SUMO1 were pooled 
and protein concentration was determined to 2 µg/µl by comparison to defined concentration of 
α-Lactalbumine (14.2 kDa) (Figure 8-C).  
C 
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Figure 8  Purification of recombinant SUMO1. SUMO1 expression was IPTG induced in BL21 gold, enriched on Q sepharose beads 
prior separation by size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram of SUMO1 on a S200 
gelfiltration column. The x-axis represents the eluted volume in sample fractions (5ml) and the y-axis the protein concentration in 
mAU (milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity in mS/cm. (B) Immunoblot analyisis of 
uninduced (-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) were separated on a 12.5% SDS-PAGE. Protein was 
stained with Coomassie brilliant blue. Fractions 33 to 38 were pooled and for further usage. (C) Concentration determination of 
A 
B 
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purified SUMO1 with the reference protein α-Lactalbumine. SUMO1 protein content in 2, 1, 0.5, 0.25 and 0.12 µl was compared to 2, 
1, 0.5, 0.25 and 0.12 µg α-Lactalbumine. Concentration was determined as 2 µg/µl. 
2.4. UBC9 ACTIVITY IN COMPARISON TO AN EARLIER PREPARATION  
Ubc9´s enzymatic activities can significantly differ between various preparations. Therfore the 
newly purified Ubc9 was compared in substrate modification to an earlier Ubc9 preparation in a 
concentration dependent manner (Figure 9). As substrate E2-25K was used, which is efficiently 
modified in the absence of an E3 ligase and was available in the Pichler laboratory.  
 
Figure 9  Comparison of two different Ubc9 preparations on substrate modification. In vitro sumoylation assay with 3.5 µg E2-25K, 
4.4 µg SUMO1, 150 ng E1 and increasing concentrations of Ubc9 from two purifications was performed for 1 hour at 30 °C in the 
presence of ATP. Reactions were stopped by addition of sample buffer. Separation was on 5-20% SDS-PAGE and detection was by 
Coomassie staining. 
 
The 20 µl in vitro sumoylation reaction contained 4 µg of SUMO1, 150 ng E1, 3.5 µg E2-25K and 
increasing concentrations (60 nM to 7 µM) of Ubc9 and ATP . E2-25K was efficiently sumoylated 
at all concentrations tested and showed comparable activity to the older preparation. 
 
PURIFICATION OF SUBSTRATES 
 
E3 independent in vitro sumoyltion assays significantly differ in substrates modification 
efficiency. Substrates like RanGAP1 or TDG require traces of Ubc9 for efficient modification. 
Most other substrates (e.g.DAXX, Sp100, p53 42,45) are only weakly modified even at high levels 
of Ubc9 and only get efficiently modified in the presence of an E3. To establish the conditions for 
an E3 independent in vitro sumoylation assay I purified various well known SUMO substates to 
compare their sumoylation efficiency at various Ubc9 concentrations.  
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2.5.  PURIFICATION OF RANGAP1 
RanGAP1 has a predicted size of 63 kDa and was cloned in the plasmid pET11d under the control 
of the T7 promoter. IPTG induced expression in E.coli BL21 gold was performed at 37 °C for 4 
hours. The cells were lysed by a freeze and thaw cycle followed by subsequent Lysozyme 
treatment. Since RanGAP1 was expressed in inclusion bodies it was recovered from pellet 
fraction by denaturing conditions. The negatively charged RanGAP1 was incubated with Q 
Sepharose beads (GE Healthcare) and eluted in 1 ml fractions with RanGAP1 Elutionbuffer. 
Protein containing fractions were pooled, concentrated and applied to size exclusion 
chromatiography on a FPLC Äkta system. Protein elution was monitored via a protein density 
profile, a chromatogram which is shown in Figure 10-A. Peak fractions were analysed on a 7% 
SDS PAGE (Figure 10-B) and protein was stained with Coomassie brilliant blue. Fractions 21 to 30 
of the second peak contained high amounts of RanGAP1 and were pooled for further usage. The 
protein concentration was determined by comparison of serial dilutions of RanGAP1 with 
definded concentrations of the reference protein BSA (66 kDa). Concentration was 0.7 µg/µl 
(Figure 10-C). 
 
 
A 
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Figure 10   Purification of recombinant RanGAP1. RanGAP1 expression was IPTG induced in E.coli BL21 gold, denaturated in urea, 
dialysed to renaturate and enriched on Q Sepharose beads prior separation by size exclusion chromatography using an ÄKTA FPLC 
system. (A) Elution chromatogram of RanGAP1 on a S200 gelfiltration column. The x-axis represents the eluted volume in sample 
fractions (1 ml) and the y-axis the protein concentration in mAU (milli absorbance unit) at 280nm. The salt concentration is indicated 
as conductivity in mS/cm. (B) Immunoblot analyisis of uninduced (-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) 
were separated on a 7% SDS-PAGE. Protein was stained with Coomassie. Fractions 21 to 30 were pooled and stored for further 
usage. (C) Concentration determination of purified RanGAP1 with the reference protein BSA. A serial dilution of RanGAP1 (2, 1, 0.5, 
0.25 and 0.12 µl) was compared to defined concentrations of BSA (2, 1, 0.5, 0.25 and 0.12 µg BSA). RanGAP1 concentration was 
determined as 0.7 µg/µl. 
2.6. PURIFICATION OF GST-DAXX 
DAXX, with a predicted size of 53 kDa, was cloned in the plasmid pGEX4T under the control of 
the T7 promoter and IPTG induced expression in E.coli BL21 gold was performed at 16 °C for 5 
hours. The cells were lysed by a freeze and thaw cycle followed by subsequent Lysozyme 
treatment. GST-DAXX was enriched on GST-sepharose (GE Healthcare) and subsequently eluted 
with a Gluthatione containing GST-Elutionbuffer. 
Protein containing fractions were pooled and applied to size exclusion chromatiography on a 
FPLC Äkta system (Figure 11-A). Fractions of the major peak were analysed on a 5-20% SDS-
PAGE. GST-DAXX containing fractions 17 to 21 were pooled (Figure 11-B) and protein content 
was determined by serial dilutions of GST-DAXX compared to definded concentrations of the 
reference protein Ovalbumin (44.3 kDa). Concentration was estimated to 2 µg/µl (Figure 11-C). 
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Figure 11   Purification of recombinant GST-DAXX. GST-DAXX expression was IPTG induced in E.coli BL21 gold,  enriched on GST 
sepharose prior separation by size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram of GST-DAXX on 
a S200 gelfiltration column. The x-axis represents the eluted volume in sample fractions (0.5 ml) and the y-axis the protein 
concentration in mAU (milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity in mS/cm. (B) Immunoblot 
analyisis of uninduced (-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) were separated on a 5-20% SDS-PAGE. 
Protein was stained with Coomassie brilliant blue. Fractions 17 to 21 were pooled for further usage. (C) Concentration determination 
of purified GST-DAXX. Serial dilutions (2, 1, 0.5, 0.25 and 0.12 µl) of GST-DAXX protein were compared to 2, 1, 0.5, 0.25 and 0.12 µg 
Ovalbumin. Concentration was determined as 2 µg/µl. 
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2.7. PURIFICATION OF HIS-MYC-TDG 
TDG, with a predicted size of 71 kDa, was cloned in the plasmid pET30 (His myc) under the 
control of the T7 promoter. IPTG induced expression in E.coli BL21 gold was performed at 16 °C 
for 5 hours. The cells were lysed by a freeze and thaw cycle followed by subsequent Lysozyme 
treatment. His-myc-TDG was enriched on Ni2+-beads (Invitrogen) which bind the His- tag in TDG. 
The bound His-myc-TDG protein was eluted with imidazole containing His-Elutionbuffer and 
protein containing fractions were pooled and applied to size exclusion chromatiography on a 
FPLC Äkta system (Figure 12-A). Factions of the first peaks were analysed on a 5-20% SDS-PAGE 
(Figure 12-B). Fractions 7-10 and 11-13 were pooled seperatly. Protein concentration (pooled 
fraction 11-13) was determined by comparison of serial dilution of His-myc-TDG to definded 
concentrations of the reference protein Phosphorylase (97.2 kDa). Concentration was estimated 
to 2 µg/µl (Figure 12-C). 
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Figure 12  Purification of recombinant His-myc-TDG. His-myc-TDG expression was IPTG induced in E.coli BL21 gold, enriched on Ni2+ 
beads prior separation by size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram of His-myc-TDG on a 
S200 gelfiltration column. The x-axis represents the eluted volume in sample fractions (0.5 ml) and the y-axis the protein 
concentration in mAU (milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity in mS/cm. (B) Immunoblot 
analyisis of uninduced (-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) were separated on a 5-20% SDS-PAGE. 
Protein was stained with Coomassie brilliant blue. Fractions 11 to 13 were pooled for further usage. (C) Concentration determination 
of purified His-myc-TDG with the reference protein Phosphorylase. Concentration was determined as 2 µg/µl. 
 
3. IN-VITRO SUMOYLATION ASSAYS OF DIFFERENT SUMO SUBSTRATES 
 
Different in-vitro sumoylation assays with known SUMO substrates were performed to identify 
optimal conditions for the ProtoArray and to verify the activity of the purified SUMO enzymes. 
3.1. RANGAP1 
RanGAP1, the Ran GTPase activating protein, was the first mammalian SUMO substrate 
identified. It was shown to be very efficiently sumoylated in the absence of an E3 Ligase 3,4 and it 
only requires little amounts of the E2 enzyme Ubc9 for efficient RanGAP1 sumoylation 39.  
2.2 µM RanGAP1 was modified in the presence of 4 µM HA-SUMO, 100 nM E1 and decreasing 
concentrations (50 nM to 0.4 nM) of Ubc9 or S*Ubc9 at 30 °C for 30 minutes. The reaction was 
stopped with Leammli buffer and samples were resolved on 5-20% SDS PAGE followed by 
immunoblotting was with HA (Figure 13-A) and RanGAP1 (Figure 13-B) antibodies. Whereas the 
HA antibody only recognizes the SUMO modified RanGAP1 species the RanGAP1 antibody 
detects both, modified and unmodified RanGAP1. Under these conditions, RanGAP1 was 
sumoylated at already the lowest Ubc9 concentration (0.4 nM). 
B 
C 
 
33 Results 
 
 
Figure 13  In vitro sumoyation of RanGAP1. RanGAP1 (2.2 µM) was sumoylated in the the presence of 4 µM HA-SUMO1, 100 nM E1 
and indicated concentrations of of Ubc9 at 30 °C for 30 minutes. Reaction was stopped with Laemmli buffer and samples were 
separated on 5-20% SDS PAGE (A) Immunostaining with HA antibodies (1:1500). (B) Immunostaining with RanGAP1 antibodies 
(1:5000). 
3.2. E2-25K 
Next, E2-25K, a ubiquitin E2 conjugating enzyme was investigated. It is another known SUMO 
substrates which gets modified without the help of an E3 ligase in vitro 10. 
2.2 µM E2-25K were incubated with 4 µM HA-SUMO1, 100 nM E1 and decreasing concentrations 
of Ubc9 (500 to 20 nM). The reaction was stopped with Leammli buffer and samples were 
separated on 5-20% SDS PAGE followed by immunoblotting with anti-HA antibodies as shown in 
Figure 14-A and with anti-E2-25K antibodies as shown in Figure 14-B. Compared to RanGAP1, E2-
25K sumoylation depended on much higher Ubc9 concentrations for efficient modification. 
 
 
Figure 14  In vitro sumoylation of E2-25K. E2-25K (2.2 µM) was sumoylated in the presence of 4 µM HA-SUMO1, 100 nM E1 and 
indicated concentrations of Ubc9 at 30 °C for 60 minutes. (A) Immunostaining with HA antibodies (1:1500). (B) Immunostaining with 
E2-25K antibodies (1:2000). 
A 
B 
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3.3. GST-DAXX 
Daxx is a SUMO substrate which depends on an E3 ligase for efficient SUMO modification. 
625 nM of Gst-Daxx were incubated with 4 µM HA-SUMO1, 100 nM E1 and decreasing 
concentrations of Ubc9 (1000 to 100 nM). Reaction was stopped with Leammli buffer and 
samples were separated on 5-20% SDS PAGE followed by detection with anti-HA antibodies 
(Figure 15-A) and anti-GST antibodies (Figure 15-B). Although extremely high concentrations of 
Ubc9 were used only traces of Gst-Daxx was sumoylated suggesting the requirement of an E3 
ligase for efficient modification.  
 
 
Figure 15  In vitro sumoylation of GST-Daxx. GST-Daxx (625 nM) was sumoylated in the presence of 4 µM HA-SUMO1, 100 nM E1 
and with indicated concentrations of Ubc9 at 30 °C for 60 minutes. (A) Immunostaining with HA antibodies (1:1500). (B) 
Immunostaining with GST antibodies (1:7000). 
 
3.4. HIS-MYC-TDG 
The SUMO substrate TDG was modified in the absence of an E3 ligase in vitro.  
357 nM of His-myc-TDG were incubated with 4 µM HA-SUMO1, 100 nM E1 and decreasing 
concentrations of Ubc9 (500 to 20 nM). The reaction was stopped with Leammli buffer and 
samples were separated on 5-20% SDS PAGE. Signals were detected with anti-HA antibodies 
(Figure 16-A) and anti-Myc antibodies (Figure 16-B). 
As shown in Figure 16-B already 100 nM Ubc9 converted more than half of His Myc-TDG to its 
sumoylated form and at 250 nM Ubc9 nearly 100% TDG sumyolation was achieved. 
A 
B 
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Figure 16   In vitro sumoylation of His myc TDG. His-myc-TDG (357 nM) was sumoylated in the presence of 4 µM HA-SUMO1, 100 
nM E1   with indicated concentrations of Ubc9 at 30 °C for 60 minutes. (A) Immunostaining with HA antibodies (1:1500). (B) 
Immunostaining with Myc antibodies (1:10000). 
 
The analysis of several known SUMO substrates in this study but also in former studies indicated 
that only a few substrates are efficiently modied in the presence of 100 nM Ubc9 (RanGAP1, 
TDG, E2-25K) whereas most other substrates depend on either higher E2 concentrations or the 
presence of an E3 ligase to obtain detectable modification (Sp100, DAXX, PML, HDAC4 42).  
Therefore the concentrations of 100 nM Ubc9, 100 nM E1 and an excess of 4 µM HA-SUMO1 
were chosen as the optimal condition for performing the SUMO in-vitro reaction on the 
ProtoArray™ to detect putative E3 independent SUMO substrates.  
  
A 
B 
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4. PROTOARRAY 
 
To gain novel insights into E3 independent substrate sumoylation it is of great interest to identify 
additional substrates which are modified in an E1/E2 dependent manner. Performing an in vitro 
sumoylation on a human protein microarray (ProtoArray) offers a novel and rapid tool to identify 
such substrates: purified enzymes are applied on the arrays and candidate substrates can be 
quickly identified 120. Thousands of human proteins are spotted in duplicates on the array. 
Multiple gene families are represented such as kinases, membrane-associated proteins, cell-
signalling proteins, metabolic proteins and many more.  
For my project the ProtoArray Human Protein Microarrays v5.0 was used. The human protein 
collections on the protoarray are human clones which were obtained either from the Invitrogen 
UltimateTM ORF (open reading frame) collection or from a Gateway® collection of kinase clones 
(by Protometrix). Each clone’s nucleotide sequence was verified by full length sequencing. All 
clones were then transferred into a system for expressing recombinant proteins in insect cells 
via baculovirus infection. Proteins are expressed at high levels in insect cells which are related to 
mammalian cells with respect to protein folding and post-translational modifications such as 
phosphorylation and glycosylation. This is a great adventage compared to proteins expressed in 
E.coli. 
 
An in-vitro sumoylation reaction was performed on such an array and upon extensive washing 
steps HA-SUMO1 modified proteins were detected with mouse anti-HA antibodies (Figure 17). 
Using a fluorescent (Alexa Fluor 647) conjugated secondary rabbit anti-mouse antibody allowed 
the readout in a fluorescent microplate reader.  
The enzyme concentration dependent increase in substrate modification is a hallmark of an 
enzymatic reaction and therefore two different Ubc9 concentrations were used instead of 
reactions in duplets. Since no reference assays comparing in vitro sumoylation “in solution” to 
such assays “on slides” were available, we decided to use 100 nM Ubc9 as estimated (see above) 
but also a five times higher concentration Ubc9 (500 nM) in case the assay is less sensitive. The 
assay buffer and the concentrations of HA-SUMO1 (4 µM), the E1 (100 nM) and ATP remained 
unchanged to the “in solution” sumoylation assays. As control we used a reaction lacking Ubc9 
to confirm E2 dependence and also to distinguish proteins that are covalently modified with 
SUMO from putative SUMO binding proteins. As an additional negative control the detection 
reagent alone was used to exclude unspecific background signals. The reactions performed are 
summarized in Table1. 
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Figure 17  Model of the ProtoArray™ for the Ubc9 assays. The ProtoArray™ which contained more than 9000 recombinant human 
proteins spotted in duplicates on glass slides was used for performing an in-vitro sumoylation reaction with HA-SUMO1(4 µM), E1 
(100 nM) and two different Ubc9 concentrations (100 nM and 500 nM). After Incubation for 1 hour at 30 °C, slides were extensively 
washed and incubated with anti-HA antibodies for 90 minutes at 4 °C. Follwing additional washing steps the glass sides 
wereincubated with a secondary Alexa Fluor 647 labeled anti-mouse antibodies for 90 minutes at 4 °C .Before drying and scanning 
addional washing steps were included.  
 
 
Table 1 Assay conditions for the different assays on the ProtoArray 
Assay E1 Ubc9 HA-
SUMO1 
Negative control - - - 
E1 control 100 nM - 4 µM 
100 nM Ubc9 100 nM 100 nM 4 µM 
500 nM Ubc9 100 nM 500 nM 4 µM 
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A small percentage (less than 0.5%) of the proteins exhibited significant signals in the negative 
control (detection reagent only) assay due to interaction with the detection reagents and were 
therefore eliminated from the analysis. 
Maximal signals were observed at >65 000 Relative Fluorescence Units (RFU) on all arrays 
probed with the sumoylation enzymes. Scanner settings were selected such that the saturated 
signals were observed for a small number of protein spots on the array probed with the highest 
concentration of E2. The maximum average background signal was 232 RFU and this was 
measured on the array which was probed with 500 nM Ubc9. The values indicate good-signal-to-
background levels from the samples.  
The average background values were calculated from local background pixel intensity values 
measured by the program GenePix 6.0 for all protein features on the array and reported in 
relative fluorescence units. 
 
Out of 9000 proteins spotted on the array approximately 800 proteins showed a positive signal 
in an E2 dependent manner. Many of these proteins are known SUMO substrates which 
confirmes the quality of this assay. We also detected several novel SUMO substrates which will 
be of interest for further analysis in the Pichler laboratory. From this assay alone we are not able 
to conclude if the identified substrates are modified in an E3 independent manner although the 
difference in signal intensities may indicate if a substrate rather depends on an E3 ligase or not. 
Unexpectedly, two known SUMO substrates, Mef2A and Hsf1 were identified with nearly 
maximum scores at 100 nM Ubc9 and with saturated maximal scores with 500 nM Ubc9. Both 
substrates have a PSDM and were described to depend on phosphorylation prior their 
sumoylation 58,59. This may indicate that some proteins kept posttranslation modifications from 
their expression in insect cells.  
I also analysed the proteins I have tested earlier for sumoylation efficiency. We could not draw 
any conclusions for Daxx since it was not presented on the screen and RanGAP1 showed 
unspecific signals in the E1 dependent control reactions. Sp100 which is only efficiently 
sumoylated in the presence of an E3 ligase or the sumoylated Ubc9 in “in solution” sumoylation 
assays 42, was obtained with maximal scores at both Ubc9 concentrations. TDG, on the other 
side, was very efficiently modified “in solution” but showed rather low signals “on both slides”. 
This could indicate that the proteins purified in E.coli used in our “in solution” assays are not 
proberly folded or lack modifications important for sumoylation. 
To learn more about these differences I aimed to investige the two phosphorylation dependent 
SUMO substrates Mef2A and Hsf1 in “in solution” sumoylation assays.  
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4.1. PURIFICATION OF SUBSTRATES IDENTIFIED IN THE PROTOARRAY 
 
Two candidate substrates, Hsf1 and Mef2A, have been chosen to be cloned into bacterial 
expression vectors and purified in E.coli. The purified proteins were then tested in “in solution” 
sumoylation assays with different Ubc9 concentrations. 
4.1.1. HSF1 
A heat shock response is characterized by synthesis of heat shock proteins, which are molecular 
chaperons. The transcription of heat shock proteins is regulated by a family of heat shock 
transcription factors (HSF) which bind to the heat shock element (HSE) in the promoter regions 
of heat shock genes and thereby activating their expression. The phosphorylation of Hsf1 is 
strongly induced during heat shock. When Hsf1 is activated, it trimerizes, binds to DNA and 
localizes in nuclear stress granules. In these granules Hsf1 undergoes multiple marked 
phosphorylations. This is known to correlate with its transcription activity. Hsf1 contains three 
SUMO consensus sites and is known to be sumoylated at Lysine 298 which is located in the 
regulatory domain of Hsf1. This site is adjacent to several critical phosphorylation sites. It was 
shown by the Sistonen laboratory that Hsf1 S303 phosphorylation is critical for its sumoylation 
58. 
As shown in Figure 18 Hsf1 was identified as high score substrate in an E2 concentration 
dependent sumoylation reaction which implicates it as an E3 independent SUMO substrate. To 
analyse Hsf1 in solution sumoylation assays it needed to be recloned, expressed and purified. 
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Figure 18  Hsf1 Signal on the two Ubc9 ProtoArrays. Detection signal of Hsf1 on the ProtoArray incubated with the reaction mixture 
with 100 nM Ubc9 and with 500 nM Ubc9 in comparison to the E1 control assays. 
We obtained Hsf1 in the mammalian expression vector pcDNA3.1A and I have recloned it into 
the bacterial expression vector pET23a by using EcoRI and HindIII restriction sites. The correct 
sequence was verified by DNA sequencing.  
 
4.1.1.1. PURIFICATION OF HIS-HSF1 
Hsf1 was cloned as a His fusion in the plasmid pET23a (His) under the control of the T7 promoter 
and has a predicted size of 79 kDa. IPTG induced expression in E.coli BL21 gold was performed at 
16 °C for 6 hours. The cells were lysed by a freeze and thaw cycle followed by subsequent 
Lysozyme treatment. His-Hsf1 was enriched on Ni2+-beads (Invitrogen) which bind to the His tag 
in Hsf1. 
The bound His-Hsf1 protein was eluted with imidazole containing His-Elutionbuffer and protein 
containing fractions were applied to size exclusion chromatiography (S200 column) on a FPLC 
Äkta system (Figure 19-A). Peak fractions were analysed on a 10 % SDS PAGE (Figure 19-B) and 
fractions 12 to 16 were pooled. His-Hsf1 concentrations were determined by serial dilutions in 
comparison to defined concentration of the reference protein BSA (66 kDa) on a 5-20% SDS-
PAGE (Figure 19-C). The concentration of His-Hsf1 was estimated to 2 µg/µl. 
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Figure 19   Purification of recombinant His-Hsf1. His-Hsf1 expression was IPTG induced in E.coli BL21 gold, enriched on Ni2+ beads 
prior separation by size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram of His-Hsf1 on a S200 
gelfiltration. The x-axis represents the eluted volume in sample fractions (0.5 ml) and the y-axis the protein concentration in mAU 
(milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity in mS/cm. (B) Immunoblot analyisis of uninduced 
(-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) were separated by 10% SDS-PAGE. Protein was stained with 
Coomassie brilliant blue. Fractions 12 to 16 were pooled and stored for further usage. (C) Protein concentration was determination 
by comparison of different His-Hsf1 dilution to defined concentratios of the reference protein BSA on a 5-20% SDS-PAGE. 
Concentration was determined to 2 µg/µl. 
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4.1.1.2. IN SOLUTION SUMOYLATION ASSAY WITH HIS-HSF1 
In-vitro SUMO assays with purified His-Hsf1 was performed at the same conditions as used on 
the ProtoArray™ which included 4 µM HA-SUMO1, 100 nM E1 and varying concentrations of 
Ubc9 from 100 nM to 1 µM. Assays were prepared in 20 µl reaction and incubated at 30 °C for 
one hour. The reactions were stopped with 2x SDS-Laemmli buffer and resolved via 5-20% SDS-
PAGE followed by immunoblotting with anti-HA (Figure 20-A) and anti-His (Figure 20-B) 
antibodies. 
 
 
Figure 20  In vitro sumoylation of His. Hsf1.His-Hsf1 (333 nM) was sumoylated in the presence of 4 µM HA-SUMO1, 100 nM E1 and 
indicated concentrations of Ubc9 at 30°C for 60 minutes. (A) Immunostaining with HA antibodies (1:1500). (B) Immunostaining with 
His antibodies (1:1000). 
 
The HA immunoblot indicates sumoylation of Hsf1 already at 100 nM Ubc9. Hsf1 modified with 
SUMO at 100 nM Ubc9 could not be detected with the less sensitive His-antibody (Figure 20-B).  
 
Hsf1 contains a PDSM and was shown to get sumoylated at Lysine 298 after phosphorylation at 
Serine 303. The research group of Lea Sistonen observed that a S303 phosphorylation deficient 
mutant could not be sumoylated whereas a mutant which mimics S303 phosphorylation 
significantly promotes Hsf1 sumoylation in vivo 58. This indicates that Serine 303 phosphorylation 
is required for efficient K298 sumoylation in vivo. 
 
However the His-Hsf1 I have purified and used for my in-vitro assays is not phosphorylated 
because it was purified from bacteria. Therefore it is expected that Hsf1 sumoylation is even 
more enhanced if Hsf1 would be prior phosphorylated.  
A 
B 
 
43 Results 
4.1.2. MEF2A 
Myocyte-enhancement factor 2 (MEF2) is a transcription factor and another substrate for 
phosphorylation dependent SUMO modification 121. It is expressed in the mammalian brain 
during the synaptogenesis. When Mef2 is sumoylated, it promotes in postsynaptic dendritic 
differentiation. SUMO modification in Mef2A occurs primarily on a lysine residue that is part of 
the PDSM 60. 
 
Mef2A was characterized as a potential E3 independent substrate on the ProtoArray™ by 
exhibiting high signals at both concentrations of Ubc9 (Figure 21). 
 
Figure 21 Mef2A Signal on the two Ubc9 ProtoArrays. Detection signal of Mef2A on the ProtoArray incubated with the reaction 
mixture with 100 nM Ubc9 and with 500 nM Ubc9 in comparison to the E1 control assay. 
 
Mef2A was cloned from the pcDNA3.1A mammalian expression vector by amplifying with primes 
containing EcoRI and XhoI restriction sites. The amplicon from the PCR was digested with these 
restriction enzymes and ligated into the bacterial expression vector pGEX6p.1 which encodes a 
GST tag. 
4.1.2.1. PURIFICATION OF GST-MEF2A 
Mef2A was cloned in the plasmid pGEX 6p.1 (GST) under the control of the T7 promoter and 
with a predicted size of 75 kDa IPTG induced expression in E.coli BL21 gold was performed at  
16 °C for 6 hours. The cells were lysed by a freeze and thaw cycle followed by subsequent 
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Lysozyme treatment. Upon enrichment on gluthatione Sepharose (GE Healthcare) GST-Mef2A 
was eluted with Gluthatione containing GST-Elutionbuffer. 
Protein containing fractions were pooled and applied to size exclusion chromatiography (S200) 
on a FPLC Äkta system (Figure 22-A). Peak fractions were analysed on a 10% SDS-PAGE (Figure 
22-B) and fractions 17 to 20 from the major peak were collected. Protein content was 
determined by serial dilutions of the reference protein BSA (66 kDa) and GST-Mef2A on a 5-20% 
SDS-PAGE (Figure 22-C). The concentration of GST-Mef2A was estimated to 0.125 µg/µl. 
 
 
 
Figure 22  Purification of recombinant GST-Mef2A. GST-Mef2A expression was IPTG induced in BL21 gold, dialysed, enriched on GST 
beads prior separation by size exclusion chromatography using an ÄKTA FPLC system. (A) Elution chromatogram of GST-Mef2A on a 
A 
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S200 gelfiltration. The x-axis represents the eluted volume in sample fractions (0.5 ml) and the y-axis the protein concentration in 
mAU (milli absorbance unit) at 280nm. The salt concentration is indicated as conductivity in mS/cm. (B) Immunoblot analyisis of 
uninduced (-IPTG) and induced (+IPTG) cells and eluted peak fractions from (A) were separated by 10% SDS-PAGE. Protein was 
stained with Coomassie brilliant blue. Fractions 17 to 21 were pooled and stored for further usage. (C) Concentration determination 
of purified GST-Mef2A with the reference protein BSA on a 5-20% SDS-PAGE. GST-Mef2A1 protein content in 2, 1, 0.5, 0.25 and 0.12 
µl was compared to 2, 1, 0.5, 0.25 and 0.12 µg BSA. Concentration was determined as 0.125 µg/µl. 
 
4.1.2.2. IN SOLUTION SUMOYLATION ASSAY WITH GST-MEF2A 
In-vitro SUMO assays with the purified GST-Mef2A was performed at the same conditions as the 
ProtoArray™ which included 4 µM HA-SUMO1, 100 nM E1 and varying concentrations of Ubc9 
from 100 nM to 1 µM. Assays were prepared in 20 µl and incubated at 30 °C for one hour. Then 
the reactions were stopped with 2x SDS-Laemmli buffer and analysed on a 5-20% SDS-gradient 
gel followed by immunostaining with anti-HA- (Figure 23-A) and anti-GST- (Figure 23-B) 
antibodies. 
 
 
Figure 23  In vitro sumoylation of GST-Mef2A. GST-Mef2A (641 nM) was sumoylated in the presence of 4 µM HA-SUMO1, 100 nM E1 
and indicated concentrations of Ubc9 at 30 °C for 60 minutes. (A) Immunostaining with HA antibodies (1:1500). (B) .Immunostaining 
with GST antibodies (1:7000). 
 
GST-Mef2A was not as efficient sumoylated as His-Hsf1 under the tested conditions. At the 
highest E2 concentration (1 µM) only a small fraction of GST Mef2A was sumoylated which is not 
suprising since it also depends on phosphorylation prior to efficient sumoylation. 
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4.2. AURORA A 
Aurora A was identified as a potential substrate for Ubc9 with moderate but significant signal 
intensities increasing with Ubc9 concentrations (3831 RFU with 100 nM Ubc9 and 12148 RFU 
with 500 nM Ubc9- maximum value 65000 RFU).  
Aurora A is a Serine/Threonin Kinase and has important functions in centrosome maturation, 
spindle formation, chromosome orientation. In addition it is frequently upregulated in human 
cancers. Aurora A was shown to interact with Ubc9 and can be sumoylated in vivo and in vitro. 
Defects in its sumoylation pattern might be implicated in tumor development 122. Figure 24 
indicates the measured signal on both ProtoArrays. 
 
 
Figure 24 AuroraA Signal on the two Ubc9 ProtoArrays. Detection signal of AuroraA on the ProtoArray incubated with the reaction 
mixture with 100 nM Ubc9 and with 500 nM Ubc9. 
 
Due to the limited time during my master thesis, the cloning of AuroraA could not be completed. 
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DISCUSSION 
 
Upregulation of the sole SUMO E2 enzyme Ubc9 frequently correlates with different types of 
cancer 102,104,105,107,109. How Ubc9 could contribute to disease onset or pathogenesis in unknown 
since most SUMO substrates are assumed to be regulated at the step of E3 ligases. Although 
Ubc9 can directly interact with a SUMO consensus motif in substrates, this binding interface is 
usually not sufficient for efficient modification and requires the help of an E3 ligase.  
In the recent years different studies indicate that selected SUMO substrates do not depend on 
E3 ligases, like RanGAP1 which is the most abundant SUMO substrate in mammalian cells. 
Biochemically RanGAP1 stably interacts with Ubc9 and a second binding interface, in addition to 
the SUMO consensus site interaction, was identified. This additional interaction is not only 
required for stable Ubc9 binding (Andrea Pichler, unpublished results) but also for efficient 
modification 39. Analog mechanisms including phosphorylation and negatively charged binding 
interfaces in different substrates were identified to enhance Ubc9 interaction and SUMO 
modification. The goal of my thesis was to learn about the generality of E3 independent 
sumoylation which may explain consequences of Ubc9 overexpression. 
 
To obtain this goal I performed an E3 independent in vitro sumoylation reaction on a human 
Protein Array containing more than 9000 recombinant proteins. As negative control we used the 
same reaction without the E2 enzyme. One advantage of our screen, in comparison to other 
methods identifiying new SUMO substrates from cells by pull downs or immunopreciptiation, is 
that our assay does not depend on the expression levels of the individual proteins. This may 
allow the identification of highly regulated substrates which are only expressed upon certain 
stimuli or in specific phases of the cell cycle. One disadvantage is that recombinant proteins on 
the screen may be partially unfolded or in some cases do only represent protein domains which 
can cause false positive results.  
 
Our assay identified more than 800 putative SUMO substrates of which many were identified in 
earlier screens or described as SUMO substrates. In my thesis I concentrated on two of such 
substrates: Hsf1 and Mef2A which showed extremely high values in our screen. I expressed 
these substrates in bacteria and tested them in our in vitro sumyolation assay. The bacterially 
expressed proteins depend on relatively high E2 concentrations for in vitro sumoylation which is 
not surprising because both proteins depend on phosphorylation prior to sumoylation in vivo 
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58,59. Since the proteins on the array are isolated from insect cells they could still be 
phosphorylated which would explain the discrepancy in sumoylation efficiency.  
 
During the practical work of this thesis the Lima lab mapped a basic batch on Ubc9 (Lysines 65, 
74 and 76) which recognizes the negatively charged phosphorylated Serine in MEF2A and is 
required to mediate enhanced sumoylation of phosphorylation dependent sumoylation motifs in 
vitro and in vivo 60. In addition they could show that this phosphorylation dependent 
enhancement is E3 independent. These findings support that at least some of the substrates 
identified in my thesis are modified indeed in an E3 independent manner. Our screen also 
identified rather novel, highly regulated SUMO substrates like Aurora B, which showed weak but 
significant modification values and was published while I was writing the manuscript. The 
substrates with low values in our screen are indeed regulated in an E3 independent manner is 
rather unlikely since Ubc9 can also modify E3 dependent substrates but not very efficiently even 
at high concentrations. Additional studies on several identified substrates, their interaction with 
Ubc9 and their efficiency in vitro sumoylation will be required to make general conclusions 
about E3 independent sumoylation.  
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MATERIALS AND METHODS 
 
5. MATERIALS 
5.1. REAGENTS& BUFFERS 
Ampicillin stock solution (100 mg/ml) 
Dissolve 5 gram of ampicillin in 50 millilitres of double distilled H2O. Filtersterilize and store 
aliquots at -20°C. 
 
Ammoniumpersulfate (APS) (10%) 
Dissolve 100 mg of APS (Roth) in 1 ml of double distilled H2O. Store aliquots at -20°C. 
 
ATP (100 mM) 
Mix 100 mM ATP, 100 mM Mg(OAc)2 and 20 mM HEPES pH 7.4. Titrate pH with 10 N NaOH and 
check with a pH paper. Freeze 50µl aliquots in liquid nitrogen and store at -20°C. 
 
Aprotinin (AP) (1 mg/ml stock solution) 
Dissolve 1 mg Aprotinin (ROTH 100 mg 4°C) in 1 ml 20 mM HEPES pH 7.4. Freeze aliquots in 
liquid nitrogen and store at -20°C. 
 
1% acetid acid 
Mix 10 ml of 100% acetic acid with 990 ml of double distilled H2O. Store at room temperature. 
 
Colloidal Coomassie stock solution 
Dissolve 100 g (NH4)2SO4 in 800 ml H2O. Add 20 g ortho-phosphoric acid and 1 g Coomassie 
Brilliant Blue G250 and fill to 1 l with H2O. Stirr at least 24 hours at RT before use. 
To prepare a working stock solution add 20% methanol. 
 
DTT (1,4-Dithiothreit) (1M stock solution) 
Dissolve 0.77 g of DTT powder (MG=154.2) (Roth) in 5 ml of double distilled H2O. Freeze aliquots 
in liquid nitrogen. Store at -20°C. 
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Isopropyl-β-D-thiogalactopyranosid (1M stock solution)  
Dissolve 11.92 g of IPTG powder in 50 ml double distilled H2O. Filtersterilize and freeze aliquots 
in liquid nitrogen. Store at -20°C. 
 
Kanamycin (60 mg/ml stock solution) 
Dissolve 60 mg of kanamycin in 1 ml of double distilled H2O. Filtersterilize and store aliquots at -
20°C. 
 
Laemmli-buffer (Western Blot Runningbuffer) (10x stock solution: 250 mM tris, 1.92 M glycine, 
0.5% SDS) 
Dissolve 30.28 g tris(base) with 144.13 g glycine and 5 g SDS in H2O at a total volume of 1 litre. 
Store at room temperature.  
 
LB medium 
Dissolve 10 g of bacterial peptone (tryptone), 5 g of yeast extract, 5 g of NaCl (and 15 g of agar 
for plates) in 1 litre water. Autoclave and cool down to 50-60°C. For preparation of plates: add 
the appropriate amount of antibiotics and pour the plates. Plates were stored at 4°C. 
 
Leupeptin/Pepstatin (LP) (1 mg/ml stock solution) 
Dissolve 1 mg of leupeptin (Calbiochem) and 1 mg of pepstatin A (Calbiochem) in 1 ml of DMSO. 
Freeze aliquots in liquid nitrogen. Store at -20°C. 
 
Loading Dye Solution for DNA (6x stock solution) 
0.2% Bromphenol Blue, 0.2% Xylene Cyanol FF, 60% glycerol and 60 mM EDTA. Store at room 
temperature. 
 
Mini Prep Buffer 1 
Dissolve 3.03 g tris(base) and 1.86 g Na2EDTA.2H2O in 400 ml ddH2O, adjust pH to 8.0 and fill up 
to 500 ml. Autoclave and store at room temperature. 
 
Mini Prep Buffer 2 
Dissolve 2.4 g of NaOH in 475 ml H2O and add 25 ml of 20% SDS. Autoclave and store at room 
temperature. 
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Mini Prep Buffer 3 
Dissolve 147.25 g potassium acetate in 250 ml H2O. Adjust the pH to 5.5 with glacial acetic acid 
and fill up with H2O to 500 ml. Autoclave and store at room temperature. 
 
Ovalbumin (20 mg/ml stock solution) 
Dissolve 20 mg Albumin Chicken E66 Grade VI A-2512 (from Sigma) in 1 ml double distilled H2O. 
Store aliquots at -20°C. 
 
PBS (10x stock solution) 
Dissolve 400.91 g of NaCl, 10.06 g of KCl, 89 g of Na2HPO4x 2H2O and 12.25 g of KH2PO4 in 
distilled H2O at a total volume of 5 litres . Titrate the pH with NaOH to 7.4. Store at room 
temperature. 
 
PBS Tween (To wash western blots)  
Mix 1 litre of the 10x PBS stock and 100 ml of 20% Tween 20. Fill up with distilled H2O to 10 
litres. Store at room temperature. 
 
PMSF (Phenylmethylsufonyl flouride) (100 mM stock solution) 
Dissolve 870 mg of PMSF in 50 ml isopropanol. Store aliquots at -20°C. 
 
Ponceau-staining solution (0.5 % Ponceau S) 
Dissolve 1 g of Ponceau S in 200 ml 1% acetic acid. Store at room temperature. 
 
Protein Purification Elution buffer 
 High Salt Elution Buffer (300 mM NaCl) 
25 mM Na-phosphate pH 6.5, 300 mM NaCl, 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml 
LP. 
 High Salt Elution Buffer (500 mM NaCl) 
50mM tris pH 7.5, 500 mM NaCl, 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP. 
 His Elution Buffer 
50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 1 mM beta-mercaptoethanol, 1 
µg/ml aprotinin and 1 µg/ml LP. 
 GST Elution Buffer 
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50 mM tris, 20 mM glutathione (reduced) pH 8 titrated with HCl, 1 mM DTT, 1 µg/ml 
aprotinin and 1 µg/ml LP. 
 RanGAP Elution Buffer 
50 mM tris pH 7.4, 1 M NaCl and 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP. 
 
SUMO Enzyme Transport buffer  
20 mM tris pH 8.0, 100 mM NaCl, 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml leupeptin/pepstatin. 
 
SDS-Laemmli-buffer (for SDS-PAGE) (2x stock solution) 
Mix 20 ml of 0.5 M tris pH 6.8, 20 ml of 20% SDS, 0.2 g of Bromphenolblue, 23 ml of 87% 
glycerine and 17 ml of double distilled H2O.,Add 20ml of DTT shortly before usage. Store at room 
temperature. When DTT is added, the buffer can be used for a maximum of two days.  
 
SUMO Assay Buffer (SAB) 
Mix 1 ml of 10x Transportbuffer, 100 µl of ovalbumin (20 µg/µl), 250 µl of 2% Tween and 10 µl of 
LP (1 mg/ml), 10 µl of aprotinin (1mg/ml) and 10 µl of 1 M DTT with 8520 µl ddH20. Store 
aliquots at – 20°C. 
 
Transportbuffer (10x stock solution) 
200 mM HEPES, 1.1 M KOAc, 20 mM Mg(OAc)2 and 10 mM EGTA pH 7.3 titrated with KOH in 
distilled H2O. Store at 4 °C. 
 
TAE (50x stock solution) 
Dissolve 242 g tris(base) (2M), 57.1 ml of 100% acetic acid and 100ml of 0.5 M EDTA pH 8.0 in 1 
litre distilled H2O. Titrate the pH of the solution with HCl to 7.7. Store the buffer at room 
temperature. 
 
Western blot transfer buffer (10x stock solution) 
250 mM tris(base), 1.93 M glycine in distilled H2O. To prepare one litre of a 1x western blot 
transfer buffer solution, mix 100ml of the 10x stock, 200m of tech. methanol, 1.8 ml of 20% SDS 
and 700ml of distilled H2O. Store the solution at room temperature. 
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5.2. PLASMIDS 
Table 2 List of different Plasmids 
Protein and Plasmid Source Selection Marker 
hSUMO1ΔC4 in pET11a Pichler et al. 200229 Amp 
HA-SUMO1ΔC4 in pET23a Melchior Lab Amp 
His-Aos1 in pET28a Pichler et al. 200229 Kan 
Uba2-His in pET28a Melchior Lab Kan 
hUbc9 in pET23a Pichler et al. 200229 Amp 
RanGAP1 in pET11d  Mahajan et al 1997 4 Amp 
DAXX in pGEX4T (residue 572-740, GST-Tag) Pichler et al. 42 Amp 
TDG in pET 30 (His Myc-Tag) Takahashi et al 116 Kan 
hHsf1 in pET23a (His-Tag) Outlined in 6.8.7 Kan 
hMef2A in pGEX6p.1 (GST-Tag) Outlined in 6.8.7 Amp 
5.3. ANTIBODIES 
Table 3 List of different Antibodies 
Antibody Made by Working Dilution Storage 
rabbit α-GST Ludger Hengst 1:7000 Stored at -20°C 
mouse α-His Qiagen 1:1000 Stored at -20°C 
mouse α-Myc Egon Ogris 1:10000 Stored at 4 °C 
mouse α-SUMO1 Zymed 1:1000 Stored at -20 °C 
goat α-hUBC9 Andrea Pichler 1:2000 Stored at -20 °C 
goat α-RanGAP1 Andrea Pichler 1:5000 Stored at 4 °C 
goat α-E2-25K Andrea Pichler 1:2000 Stored at -20 °C 
monoclonal mouse α-HA.11 Covance 1:1500 Stored at -20 °C 
HRP-coupled α-mouse, α-goat 
and α-rabbit antibodies 
Jackson Laboratories 1:10 000 Stored at -20 °C 
Alexa647 labelled α-mouse 
antibody 
Invitrogen 1:2000 Stored at -20 °C 
5.4. REFERENCE PROTEINS 
α-Lactalbumine [10mM]   14.2 kD  
Trypsine Inhibitor [10mM]  20.1 kD 
Ovalbumine [10mM]   44.3 kD 
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BSA [2mM]    66.0 kD 
Phosphorylase A [1mM]  97.2 kD 
 
6. METHODS 
6.1. PCR 
6.1.1. PRIMER DESIGN 
To design a primer several things should be considered: the forward primer should start with 6 
random bases upstream of the restriction site to support the restriction enzyme. The restriction 
enzyme site should be found in the multiple cloning site of the vector but not in the gene of 
interest. The restriction site is followed by the start ATG of the gene and additional 20 to 25 
bases of the gene of interest, which should end with a C or G for better annealing. The length of 
the primer should not exceed more than 60 bases. The ratio between A/T and C/G should be 
about 50%. The reverse primer was designed complementary to the forward primer. 
6.1.2. PCR REACTION 
PCR reactions were performed with Phusion High Fidelity DNA Polymerase (Finnzymes, Thermo 
Fisher). For a reaction volume of 50 µl following amounts were needed: 1U (0.5 µl) Phusion, 10 
mM dNTPs (1 µl), 5x Phusion buffer, 10 pmol/µl forward Primer and 10 pmol/µl reverse Primer 
(2.5 µl), x µl template DNA (approximately 10 – 20 ng should be sufficient) and autoclaved 
double distilled H2O. Cycling conditions for the thermal cycler are illustrated in Table 4: 
 
Table 4 PCR conditions 
Cycle Step Temperature Time Cycles 
Initial denaturation 98°C 30 sec 1 
Denaturation 98°C 5-10 sec 35x 
Annealing x°C 30 sec 35x 
Extension 72°C 15-30s/kb 35x 
Final Extension 72°C 5-10 min 1 
Hold 4°C hold  
 
The annealing temperature is calculated by counting the bases of the primer (without restriction 
sites and the additional bases) and multiplying the number of adenines and thymines by 2 and 
the number of guanines and cytosines by 4.  
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Alternatively (if the optimal annealing temperature is not certain), a gradient PCR can be 
performed. Then a gradient ranging from 60°C to 70°C can be set at the annealing step. The PCR 
product was analysed via agarose gel electrophoresis. 
6.2. AGAROSE GEL ELECTROPHORESIS 
DNA samples were resolved via 1% or 0.8% agarose gel electrophoresis in TAE buffer at 100 V for 
30 min. 
Selected DNA bands were excised from the gel using a clean scalpel blade and eluted with the 
Qiaquick Gel Extraction Kit (Qiagen) following the manufactorer’s protocol. 
6.3. RESTRICTION DIGESTION AND LIGATION 
6.3.1. RESTRICTION DIGESTION 
Restriction digestions were performed in a volume of 50 µl and 1.5 µl of each restriction enzyme 
(100000 units/ml from New England Biolabs) were used. In addition 10x RNAse stock and 10x 
BSA (if needed) were added to the restriction mixture. The 10x buffer was chosen according to 
the combination of the restriction enzyme. The digestion mixture was incubated at 37°C for 1 ½ 
hours. Then the digest was mixed with the 6x loading dye solution, resolved on an agarose gel 
and the desired DNA bands were eluted.  
 
6.3.2. LIGATION 
For ligation the DNA insert and the vector were used at a ratio of 3:1. The amount of DNA was 
estimated after visualizing on an agarose gel. The ligation mixture with a final volume of 20 µl 
consisted of the insert and the vector DNA, 1 µl T4 Ligase (400000U/ml, from New England 
BioLabs), 10x T4 Ligase Buffer (New England Biolabs) and ddH2O if needed. A negative ligation 
control without the insert DNA was also performed. The two ligation mixtures were incubated at 
room temperature for 2 hours. Afterwards the mixtures were transformed into competent 
bacteria. 
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6.4. TRANSFORMATION 
6.4.1. LIST OF COMPETENT BACTERIA 
Table 5 Competent bacteria, their function and genetics 
Strain Usage 
E.coli DH5α Transformation of Plasmids 
Rosetta C41 Protein Expression 
BL21 gold Protein Expression 
 
6.4.2. PREPARATION OF COMPETENT BACTERIA (TSS-METHOD) 
First, the TSS buffer was prepared: for 50 ml of buffer, 5 g of PEG 8000, 0.3 g of MgCl2.6H2O and 
2.5 ml DMSO were mixed together and filled up with LB to 50 ml. The solution was filtersterilized 
and stored at either 4°C or -20°C. 
An aliquot of competent bacteria was grown in LB with the appropriate antibiotic overnight. The 
culture was diluted 1:100 the next day and grown to OD 0.2-0.5. Then the culture was 
centrifuged for 10 minutes at 4°C (4000 rpm). The medium was removed and the pellet carefully 
resuspended in 1/10 volume of chilled TSS buffer without leaving cell clumps or aggregates. 
Finally the bacteria were aliquoted (100µl each) in pre-chilled eppendorf tubes and the aliquots 
were stored at -80°C. 
To test the transformation efficiency one aliquot of competent bacteria was transformed with a 
1:10000 dilution of plasmid DNA (approx 0.1 ng). After recovery 200µl of the transformation mix 
were plated on LB plates supplemented with the appropriate antibiotic where it should result at 
least in 100 colonies. 
6.4.3. TRANSFORMATION OF DNA IN BACTERIA 
One aliquot of competent bacteria was thawed on ice; the DNA was added (2µl of plasmid DNA 
for protein expression in BL21gold or 10µl of ligation mix in DH5α bacteria) and mixed. The mix 
was incubated on ice for 20 min followed by incubation at 42°C for 1 ½ min and another 5 min 
incubation on ice. After addition of 1 ml LB without antibiotics the mix was incubated for 1 hour 
at 37°C with 500 rpm. Then it was either added to LB with antibiotics (5 ml for overnight culture) 
or plated on a LB plate (containing the appropriate antibiotic). 
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6.5. PLASMID PREPARATION (MINI PREPARATION) 
Preparation of plasmid DNA for sequencing or transformation was performed with the QIAprep 
DNA Mini Kit from Qiagen following the corresponding protocol.  
Plasmids that were used for control restriction digestion were prepared as follows; A single 
colony was inoculated in 2 ml LB supplemented with the appropriate antibiotic and grown at 
37°C over night. The next day the culture was pelleted in a 2 millilitre Eppendorf tube by 
centrifuging for 5 minutes at 4000 rpm /or at 13 200 rpm. The pellet was resuspended in 300 µl 
buffer 1. Then 300 µl buffer 2 were added to the suspension, mixed gently and incubated for 5 
minutes at room temperature. Then 300 µl of buffer 3 were added to the mixture, it was mixed 
thoroughly and incubated for 5 minutes on ice.  
After the incubation time, the mixture was mixed again and centrifuged for 5 minutes at 14 000 
rpm on room temperature. Then the supernatant was transferred to a new 1.5 ml Eppendorf 
tube and centrifuged again for 5 minutes at 13 200 rpm. 850 µl of the supernatant were 
transferred to a new Eppendorf tube and 595 µl isopropanol were added. It was mixed well and 
centrifuged for 15 minutes at 13 200 rpm. The liquid was poured off; the pellet was washed once 
with 70% EtOH and dried on air. Then the pellet was dissolved in 20 to 50 µl H2O. 
6.6. POLYACRYLAMIDE GEL (SDS-PAGE) 
For the polymerisation of SDS Laemmli gels following materials are needed: double distilled H2O, 
2 M tris/HCl pH 8.8, 0.5 M tris/HCl pH 6.8, 30% Acrylamid: Bisacrylamid (30:0.8) Rotiphorese 
(Carl Roth), 20% SDS, ammonium persulfate (APS) (-20°C), TEMED 4°C. For the preparation of 
gradient gels (5-20%) a gradient mixer was used which contains two containers. In the container 
with the direct outlet to the gel chamber, the lower concentrated acrylamide solution is poured. 
Recipes for 10 gels 
 
Table 6 SDS-PAGE running gel recipe 
SDS running gel  5% 7% 10% 12.5% 20% 
dd H2O ml 42.9 38.35 31.3 25.5 7.9 
2 M Tris/HCl pH 8.8 ml 14 14 14 14 14 
30% AA:Bis ml 11.7 16.3 23.33 29.2 46.7 
20% SDS µl 350 350 350 350 350 
                           mix 
10% APS µl 700 700 700 700 700 
TEMED µl 70 70 70 70 70 
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Table 7 SDS-PAGE stacking gel recipe 
SDS stacking gel  2x 
dd H2O ml 45.4 
0.5 M Tris/HCl pH 6.8 ml 6 
30% AA:Bis ml 8 
20% SDS µl 300 
                                                    mix 
10% APS µl 300 
TEMED µl 60 
 
The samples were prepared by adding 2x SDS Laemmli buffer with DTT and boiling at 95 °C for 5 
minutes. After boiling the samples were loaded in the slots. Then 3 µl of PageRuler™ prestained 
Protein Ladder (Fermentas) and 7 µl of PageRuler™ unstained Protein Ladder (Fermentas) were 
loaded in the first and in the last slot, respectively. The gel run was performed at constant 
amperage of 25 mA per gel. 
 
Coomassie Staining 
Before staining with Coomassie Brilliant Blue, the gel needs to be fixed in 40% ethanol and 10% 
acetic acid for at least 15 minutes. Then the gel was washed two times with water for 10 
minutes each. Afterwards the Coomassie stock was diluted with methanol 4:1 and the gels were 
incubated with the mix overnight. The next day the gel was washed with 1% acetic acid until all 
Coomassie particles were removed. 
 
6.7. WESTERN BLOT (SEMI-DRY WESTERN BLOT) 
Proteins were transferred from the gel to a nitrocellulose membrane by semi dry blotting (15 to 
20 volt per gel for 30 minutes (45 minutes for a gradient gel)). During blotting 0.6 ampere should 
not be exceeded and a constant voltage should be maintained. 
After the transfer, the nitrocellulose membrane was washed in ddH2O for a minute and then 
shortly dyed in Ponceau. It was destained in 1% acetic acid and the protein ladder bands were 
marked with a ball pen. Then the membrane was washed in PBS-Tween until the red dye was 
removed. Afterwards the nitrocellulose membrane was incubated in 5% milk in PBS-Tween for 
30 minutes at room temperature or at 4°C overnight. 
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The membrane was washed for 10 minutes in PBS-Tween prior to incubation with the primary 
antibody, which was diluted in 5 to 10 ml of 5% milk/PBS-Tween. The incubation with the 
antibody was performed for 1 ½ to 2 hours at room temperature. Afterwards the membrane 
was washed three times with PBS-Tween for 5 minutes each. Finally the membrane was 
incubated with the secondary antibody dilution (in 5% milk/PBS-Tween) for one hour at room 
temperature followed by washing with PBS-Tween for 3 times for 10 minutes each.  
For the detection of the horseradish peroxidase enzyme activity the SuperSignal West Pico 
Chemiluminescent Substrate (Pierce/Thermo Fisher) or for further enhancement SuperSignal 
West Femto Chemiluminescent Substrate (Pierce/Thermo Scientific) was used. The 
Luminol/Enhancer and the Stable Peroxide Buffer solutions were mixed in a ratio of 1:1 and the 
membrane was incubated with the mix for one minute. Excess reagent was drained and the 
membrane was covered with a plastic foil in a western blot film cassette. In the dark room the 
“treated” membrane was exposed to an Amersham Hyperfilm™ ECL from GE Healthcare. The 
exposure time was varied to achieve optimal results. Then the films were developed in a 
developer. 
 
 
6.8. EXPRESSION OF PROTEINS 
6.8.1. EXPRESSION AND PURIFICATION OF HUMAN AOS1/UBA2 (E1) 
On the first day one aliquot of BL21 gold competent bacteria was transformed with His-Aos1 in 
pET28a and one aliquot was transformed with plasmid Uba2-His in pET28a. 5 ml of LB 
complemented with kanamycin was added to the bacteria and the two cultures were grown 
during the day at 37°C 200 rpm. In the afternoon the cultures were transferred to 40 ml LB with 
kanamycin and grown overnight.  
The next day each culture was diluted to 2 litres and grown to an OD600 of 0.5 to 0.6. Then 1 ml 
aliquot of each culture was taken, centrifuged at 4000 rpm at room temperature, the LB was 
removed and the bacterial pellets were resuspended in 50 µl of 2x SDS-Laemmli buffer and 
boiled at 95°C for 5 minutes. Protein expression was induced by adding IPTG at a final 
concentration of 1 mM from a 1000x stock. The two cultures were incubated at 25°C 200 rpm 
for 6 hours. Aliquots of the induced cultures were taken every hour.  
After the 6 hours bacteria were harvested by centrifugation for 20 minutes at 4°C and 4000 rpm 
in a Sorvall RC-5 Superspeed refrigerated centrifuge with a Sorvall GS-3 rotor. The pellets were 
resuspended in 30 ml (15 ml/litre culture) of icecold lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 
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10 mM imidazole, 0.1 mM PMSF, 1 mM beta-mercaptoethanol, 1 µg/ml aprotinin and 1 µg/ml 
LP). Both pellets were frozen in liquid nitrogen and stored at -80°C. 
On day 3 the pellets were thawed and split in ultrazentrifuge tubes for Beckmann rotor 50.2Ti. 1 
mg/ml lysozyme was added to the suspension and incubated for one hour on ice. Then they 
were ultracentrifuged for one hour in the ultracentrifuge Beckman (Optima) XL at 4°C and 100 
000g. In the meantime 2x 2.5 ml/litre culture of Ni-Beads (ProBondTM resin from Invitrogen) 
were equilibrated with icecold lysis buffer by washing 2 to 3 times with at least one column 
volume. 
 
The supernatant after ultracentrifugation was pooled and added to the equilibrated Ni-beads 
and incubated while rotating for 1.5 hours at 4°C. Ni-beads were then harvested by 
centrifugation for 5 minutes at 4°C and 1000 rpm. The beads bound with the protein were 
transferred into a column and the beads were washed extensively with ice-cold wash buffer (50 
mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 1 mM beta-mercaptoethanol, 1 µg/ml aprotinin 
and 1 µg/ml LP). Then the proteins were eluted with 15x 0.5 ml icecold His elution buffer. To 
identify the fractions containing the eluted protein, 1 µl of each fraction was spotted on a 
nitrocellulose membrane and stained with Ponceau S.  
The peak fractions were pooled (3 to 5 ml) and concentrated to 1 ml using Vivaspin columns 
(Sarstedt) or Centricons (Millipore) and then centrifuged for 10 minutes in the ultracentrifuge. 
One millilitre was applied to the ÄKTA S200 preparative gelfiltration column. The column was 
already equilibrated in icecold transport buffer, complemented with 1 mM DTT, 1 µg/ml 
aprotinin and 1 µg/ml LP. The flow rate of the ÄKTA was to 0.5 ml/minute and 0.5 ml fractions 
were collected. The fractions were analysed via a chromatogram (a protein density profile) and 
via SDS-PAGE where 10 µl of each peak fraction was analysed on a 5-20 % gradient gel  
For Aos1 peak fractions 7 to 17 were pooled and peak Uba2 fractions 9 to 16 were pooled, 
frozen in liquid nitrogen and stored at -80°C.  
On day 4 the dimeric SUMO E1 was reconstituted and therefore equimolar amounts of His-Aos1 
and Uba2-His were combined. The required ratio of Aos1 and Uba2 was determined by 
comparing serial dilutions of each enzyme side by side on a SDS-polyacrylamid gel. Aos1 and 
Uba2 were combined at a ratio of 1:2 and incubated on ice for 2 hours. Then the sample was 
applied to the HiLoad 26/60 S200 ÄKTA column that was equilibrated in SUMO enzyme transport 
buffer. The flow rate of the ÄKTA was set to 2.5 ml/min and fractions of 5 ml were collected. 
(Fractions 32 to 47 were tested on a coomassie gel for the dimeric E1). Fractions that contain 
equal amounts of Aos1 (40kDa) and Uba2 (90kDa) (fractions 35 to 37) were pooled and 
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subsequently aliquoted into 10 µl, 20 µl, 50 µl, 100 µl, 200 µl, 500 µl and 1ml, frozen in liquid 
nitrogen and stored at -80°C. The protein concentration was estimated by comparing serial 
dilutions of the protein to serial dilutions of a reference protein of known concentration via SDS 
PAGE with subsequent staining with Coomassie Brilliant Blue. The protein concentration was 
estimated as 0.5 µg/µl= 4.5 µM.  
6.8.2. EXPRESSION AND PURIFICATION OF HUMAN SUMO1 AND HA-SUMO1  
On the first day one aliquot of BL21 gold competent bacteria was transformed with plasmid 
hSUMO1ΔC4 in pET11a or with HA-hSUMO1ΔC4 in pET23a. 5 ml of LB complemented with 
ampicillin was added to the bacteria and the culture was grown during the day at 37°C 200 rpm. 
In the afternoon the culture was transferred to 40 ml LB with ampicillin and grown overnight. 
The next day the culture was diluted to 4 litres and grown to an OD600 of 0.5 to 0.6. Then 1 ml 
aliquot of the culture was taken, centrifuged at 4000 rpm at room temperature, the LB was 
removed and the bacterial pellet was resuspended in 50 µl of 2x SDS-Laemmli buffer and boiled 
at 95°C for 5 minutes.  
 
Protein expression was induced by adding IPTG to a final concentration of 1 mM from a 1000x 
stock solution. The SUMO1 culture was incubated at 37°C 200 rpm for 4 hours and the HA-
hSUMO1 culture was incubated overnight. Aliquots of the induced cultures were taken every 
hour. After the incubation time the bacteria were harvested by centrifugation at 4°C, at 4000 
rpm for 20 minutes in a Sorvall RC-5 Superspeed refrigerated centrifuge with a Sorvall GS-3 
rotor. The pellets were resuspended in 30 ml (15ml/litre culture) of icecold SUMO lysis buffer 
(50 mM tris-HCl pH 8.8, 25 mM NaCl, 0.1 mM PMSF, 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml 
LP). The pellet was frozen in liquid nitrogen and stored at -80°C. 
 
On day 3 the pellet was thawed and 0.1 mM PMSF 1 mM DTT and 1 µl/ml of aprotinin and LP, 
respectively were added. The suspension was sonicated (maximum 15 ml at once) 3 times for 30 
seconds at 75% intensity. The suspension was split into ultrazentrifuge tubes for a Beckman 
rotor 50.2Ti and ultracentrifuged for one hour at 4°C and 100 000g in the ultracentrifuge 
Beckman (Optima) XL. In the meantime 3-4 ml (=6-8 ml suspension) Q Sepharose™ Fast Flow 
beads from GE Healthcare were filled into an appropriate column and equilibrated with icecold 
SUMO lysis buffer (50 mM Tris-HCl pH 8.8, 25 mM NaCl, 1 mM DTT, 1 µg/ml aprotinin and 1 
µg/ml LP) by washing 2-3 times with at least one column volume. The supernatant after 
ultracentrifugation was quickly transferred to a column with the equilibrated Q sepharose 
beads. The column was washed 2 to 3 times with 6x column volume lysis buffer. The protein was 
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eluted with 8 ml (16x 0.5 ml) icecold high salt elution buffer (500 mM NaCl). Each fraction was 
tested for protein by spotting 1 µl on nitrocellulose membrane and staining with Ponceau.  
 
The peak fractions of hSUMO1 were pooled and applied to the ÄKTA HiLoad 26/60 S200 
preparative gelfiltration column, which was already equilibrated in icecold SUMO enzyme 
transport buffer. The flow rate of the ÄKTA was set to 1.5 ml/minute and 5 ml fractions were 
collected. The fractions were analysed via a chromatogram (a protein density profile) and via 
SDS-PAGE where 5 µl of each peak fraction were analysed on a 12.5% gel. (Fractions 19-46 were 
tested on a coomassie gel and fractions 33 to 37 were collected and pooled.)  
 
HA-SUMO1 elution fractions were applied to the Äkta S200 10/300 GL preparative gelfiltration 
column which was equilibrated in transport buffer complemented with 1mM DTT, 1μg/ml 
aprotinin and 1μg/ml LP). The flow rate was set to 0.5 ml/min and 0.5 ml fractions were 
collected and analysed via a chromatogram and the most promising fractions via SDS-PAGE. The 
best fractions of HA-SUMO1 were collected and pooled.  
Aliquots of 10 µl, 20 µl, 50 µl, 100 µl, 200 µl, 500 µl and 1ml of SUMO1 and HA-SUMO1 were 
prepared, frozen in liquid nitrogen and stored at -80°C. The protein concentration was estimated 
by comparing serial dilutions of the protein to serial dilutions of a reference protein of known 
concentration via SDS PAGE with subsequent staining with Coomassie Brilliant Blue. The 
concentration of SUMO1 was estimated as 2 µg/µl = 173 μM and of HA-SUMO1 as 1.5 µg/µl = 
100 μM. 
6.8.3. EXPRESSION AND PURIFICATION OF HUMAN UBC9  
On the first day one aliquot of BL21 gold competent bacteria was transformed with hUbc9 in 
pET23a. 5 ml of LB complemented with ampicillin was added to the bacteria and the culture was 
grown during the day at 37°C 200 rpm. In the afternoon the culture was transferred to 80 ml LB 
with ampicillin and grown overnight. The next day the culture was diluted in 12 litres 
LB/ampicillin and grown to an OD600 of 0.5 to 0.6. Then 1 ml aliquot of the culture was taken, 
centrifuged at 4000 rpm at room temperature, the LB was removed and the bacterial pellet was 
resuspended in 50 µl of 2x SDS-Laemmli buffer and boiled at 95°C for 5 minutes.  
Expression of the human Ubc9 protein was induced by addition of IPTG at a final concentration 
of 1 mM (from a 1000x stock solution). The culture was incubated at 37°C 200 rpm for 4 hours. 
Samples of the induced culture were taken every hour. 
After the 4 hours bacteria were harvested by centrifugation at 4°C, at 4000 rpm and for 20 
minutes in a Sorvall RC-5 Superspeed refrigerated centrifuge with a Sorvall GS-3 rotor. The 
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pellets were resuspended in 3x30 ml (15ml/litre culture) of icecold Ubc9 lysis buffer (25 mM Na-
phosphate pH 6.5, 50 mM NaCl, 0.1 mM PMSF, 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP). 
The pellets were frozen in liquid nitrogen and stored at -80°C. 
On day 3 the pellet was thawed and 0.1 mM PMSF 1 mM DTT and 1 µl/ml of aprotinin and LP, 
respectively, were added. The suspension was divided into ultrazentrifuge tubes for a Beckman 
rotor 50.2Ti and ultracentrifuged for one hour at 4°C and 100 000g in the ultracentrifuge 
Beckman (Optima) XL. In the meantime 24 ml SP SepharoseTM high performance beads from GE 
Healthcare (=2 ml suspension per litre of culture) were filled into a suitable column and 
equilibrated with icecold Ubc9 lysis buffer by washing 2-3 times with at least one column 
volume. After the ultracentrifugation the supernatant was quickly transferred to the column 
containing the equilibrated SP sepharose beads and passed the column by gravity flow. The 
beads were washed in the column for 2 to 3 times with 6x column volume of Ubc9 lysis buffer.  
Ubc9 was eluted from the beads with 35 ml icecold high salt elution buffer (300 mM NaCl). First 
10 ml of elution buffer were applied at once and the flow through was discarded. The next 25 ml 
of elution buffer were added in 1 ml steps and were collected separately. Each fraction was 
tested for protein by spotting 1 µl on nitrocellulose membrane and staining with Ponceau.  
The peak fractions were pooled and applied to the ÄKTA HiLoad 26/60 S200 preparative 
gelfiltration column that was already equilibrated in icecold SUMO enzyme transport buffer. The 
flow rate of the ÄKTA was set to 2.5 ml/minute and 5 ml fractions were collected. The fractions 
were analysed via a chromatogram (a protein density profile) and via SDS-PAGE where 10 µl of 
each peak fraction were analysed on a 12.5% SDS-PAGE gel. Fractions containing high amounts 
of Ubc9 (fractions 51 to 53) were pooled and aliquots of 10 µl, 20 µl, 100 µl and 1 ml were 
prepared, frozen in liquid nitrogen and stored at -80°C.  
6.8.4. EXPRESSION AND PURIFCATION OF RANGAP1 
On the first day one aliquot of BL21 gold competent bacteria was transformed with RanGAP1 in 
pET11d. 5 ml of LB complemented with ampicillin was added to the bacteria and the culture was 
grown during the day at 37°C 200 rpm. In the afternoon the culture was transferred to 40 ml LB 
with ampicillin and grown overnight. The next day the culture was diluted in 2 litres LB/ampicillin 
and grown to an OD600 of 0.5 to 0.6. Then 1 ml aliquot of the culture was taken, centrifuged at 
4000 rpm at room temperature, the LB was removed and the bacterial pellet was resuspended 
in 50 µl of 2x SDS-Laemmli buffer and boiled at 95°C for 5 minutes.  
Expression of the RanGAP protein was induced by addition of IPTG at a final concentration of 1 
mM from a 1000x stock solution. The culture was incubated at 37°C 200 rpm for 4 hours. 
Aliquots of the induced culture were taken every hour. 
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After the 4 hours the bacteria were harvested by centrifugation at 4°C, at 4000 rpm and for 20 
minutes in a Sorvall RC-5 Superspeed refrigerated centrifuge with a Sorvall GS-3 rotor. The 
pellets were resuspended in 30 ml (15ml/litre culture) of icecold lysis buffer (50 mM Tris.HCl pH 
8, 100 mM NaCl, 0.1 mM PMSF, 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP), frozen in liquid 
nitrogen and stored at -80°C. 
On day 3 the pellet was thawed, split into ultrazentrifuge tubes for Beckman rotor 50.2Ti 1 
mg/ml lysozyme was added to the suspension and incubated for one hour on ice. After 
ultracentrifugation for 30 min in the ultracentrifuge Beckman (Optima) XL at 4°C and 75000g the 
pellet was washed two times with RanGAP1 wash buffer 1 (50 mM Tris pH 8, 1% Triton-X100) 
and one time with RanGAP1 wash buffer 2 (2 M Urea, 50 mM Tris pH 7.4), the pellet was 
resuspended with a douncer and subsequently ultracentrifuged in the Beckman rotor 50.2Ti at 
75000g for 30 min. The remaining pellet was solubilized in RanGAP1 lysis buffer 1 (8 M Urea, 50 
mM Tris pH 7.4). The solubilized pellet was dialyzed over night against 2 l RanGAP1 lysis buffer 2 
50 mM Tris pH7.4, 150 mM NaCl, 0.1 mM PMSF, 1 mM DTT, 1 µg/ml aprotinin, 1 µg/ml 
leupeptin/pepstatin. The buffer was changed two times. 
The next day the solubilized and dialyzed pellet was ultracentrifuged for 30 min at 75000g at 
4°C. In the meantime 15 ml Q Sepharose beads were equilibrated with (50 mM tris pH 7.4, 150 
mM NaCl and 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP). For the equilibration step the beads 
were washed for 2-3 times for at least one column volume. After ultracentrifugation the 
supernatant was applied to the equilibrated beads. The beads were washed with 50 mM tris pH 
7.4, 300 mM NaCl and 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP. To elute the bound RanGAP 
15 x 1 ml fractions of RanGAP1 elution buffer were applied to the beads. Each fraction was 
collected and tested for protein by spotting 1 µl on nitrocellulose membrane and staining with 
Ponceau. The peak fractions were pooled, concentrated and ultracentrifuged for 10 min.  
 
Then the sample was applied to the ÄKTA S200 column which was already equilibrated in icecold 
degased transportbuffer complemented 1mM DTT, 1μg/ml aprotinin and 1μg/ml LP. The flow 
rate was set on 0.5 ml/min and fractions of 0.5 ml were collected. The fractions were analysed 
via a chromatogram (a protein density profile) and via SDS-PAGE where 10 µl of each peak 
fraction were analysed on a 7 % gel. Fractions (21 to 30) that contained a protein with 65 kDa 
were united. Aliquots of 10 µl, 20 µl, 50 µl, 100 µl, 200 µl and 500 µl were prepared, frozen in 
liquid nitrogen and stored at -80°C. The protein concentration was estimated as 0.7 µg/µl= 11 
µM with a reference protein on SDS PAGE. 
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6.8.5. EXPRESSION AND PURIFICATION OF GST-DAXX 
On the first day one aliquot of BL21 gold competent bacteria was transformed with pGEX4T-
DAXX. 5 ml of LB complemented with ampicillin was added to the bacteria and the culture was 
grown during the day at 37°C 200 rpm. In the afternoon the culture was transferred to 40 ml LB 
with ampicillin and grown overnight. The next day the culture was diluted in 2 litres 
Lb/ampicilliln and grown to an OD600 of 0.5 to 0.6. 1 ml aliquot of the culture was taken, 
centrifuged at 4000 rpm at room temperature, the LB was removed and the bacterial pellet was 
resuspended in 50 µl of 2x SDS-Laemmli buffer and boiled at 95°C for 5 minutes.  
Expression of GST-DAXX was induced with IPTG (final concentration 1 mM). The culture was 
incubated at 16°C 200 rpm for 5 hours. Aliquots of the induced culture were taken every hour. 
After the 5 hours bacteria were harvested at 4°C, at 4000 rpm and for 20 minutes in a Sorvall RC-
5 Superspeed refrigerated centrifuge with a Sorvall GS-3 rotor. The pellet was resuspended in 30 
ml (15ml/litre culture) of icecold lysis buffer (50 mM Tris.HCl pH 8, 100 mM NaCl, 0.1 mM PMSF, 
1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP). The pellet was frozen in liquid nitrogen and stored 
at -80°C. 
 
The next day the pellet was thawed and split into ultrazentrifuge tubes for Beckmann rotor 
50.2Ti. 1 mg/ml lysozyme was added to the suspension and incubated for one hour on ice. Then 
they were ultracentrifuged for one hour in the ultracentrifuge Beckman (Optima) XL at 4°C at 
100 000g. In the meantime 3 ml Glutathione Sepharose 4B (GST-beads) from GE Healthcare (1-2 
ml per litre culture) were equilibrated with lysis buffer (50 mM Tris.HCl pH 8, 100 mM NaCl, 1 
mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP) by washing 2 to 3 times with at least 15 ml buffer. 
The supernatant was quickly transferred to the equilibrated GST beads and incubated for 1.5 
hours at 4°C on rotation. The beads were harvested by centrifugation for 5 minutes at 4°C and 
1000 rpm and washed for 2 to 3 times with 10 ml icecold lysis buffer for 5 minutes at 4°C and 
1000 rpm. The beads were transferred to a column. Then the bound GST-Daxx protein was 
eluted with 5 ml icecold GST elution buffer. 10 x 0.5 ml fractions were collected and each 
fraction was tested for protein by spotting 1 µl on nitrocellulose membrane and staining with 
Ponceau.  
 
The peak fractions were pooled and concentrated in a vivaspin2 column at 4000 rpm at 4°C. The 
concentrated solution was ultracentrifuged at 100000g at 4°C for 10 min. The supernatant was 
applied to the ÄKTA S200 column which was already equilibrated in icecold degased 
transportbuffer complemented with 1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP. The flow rate 
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was set on 0.5 ml/min and fractions of 0.5 ml were collected. The fractions were analysed via a 
chromatogram (a protein density profile) and via SDS-PAGE by analyzing 10 µl of each peak 
fraction on a 5-20% SDS-PAGE. Protein-containing fractions (13 to 15) were collected and 
pooled. Aliquots of 10 µl, 20 µl, 50 µl, 100 µl, 200 µl and 500 µl were prepared, frozen in liquid 
nitrogen and stored at -80°C. The protein concentration was estimated as 2 µg/µl= 40 µM with a 
reference protein on SDS-PAGE. 
6.8.6. EXPRESSION AND PURIFICATION OF HIS-TDG 
On the first day one aliquot of Rosetta C41 competent bacteria was transformed with pET His 
Myc TDG. 5 ml of LB complemented with kanamycin was added to the bacteria and the culture 
was grown during the day at 37°C 200 rpm. In the afternoon the culture was transferred to 40 ml 
LB with kanamycin and grown overnight. The next day the culture was diluted in 2 litres 
LB/kanamycin and grown to an OD600 of 0.5 to 0.6. Then 1 ml aliquot of the culture was taken, 
centrifuged at 4000 rpm at room temperature, the LB was removed and the bacterial pellet was 
resuspended in 50 µl of 2x SDS-Laemmli buffer and boiled at 95°C for 5 minutes.  
Expression of His-TDG was induced by addition of IPTG at a final concentration of 1 mM. The 
culture was incubated at 16°C 200 rpm for 5 hours. Aliquots of the induced culture were taken 
every hour. After the 5 hours bacteria were harvested via centrifugation at 4°C, at 4000 rpm and 
for 20 minutes in a Sorvall RC-5 Superspeed refrigerated centrifuge with a Sorvall GS-3 rotor. The 
pellet was resuspended in 30 ml (15ml/litre culture) of icecold lysis buffer (50 mM NaH2PO4, 300 
mM NaCl, 10 mM imidazol, 0.1 mM PMSF, 1 mM beta-mercaptoethanol, 1 µg/ml aprotinin and 1 
µg/ml LP). The pellet was frozen in liquid nitrogen and stored at -80°C. 
The next day the pellet was thawed and divided into ultrazentrifuge tubes for a Beckman rotor 
50.2Ti. 1 mg/ml lysozyme was added to the suspension and incubated for one hour on ice 
followed by ultracentrifugation for one hour in the ultracentrifuge Beckman (Optima) XL at 4°C 
at 100 000g. In the meantime 5 ml ProBondTM resin (Ni-Beads) from Invitrogen (2-3 ml per litre 
culture) were equilibrated with lysis buffer (50 mM tris.HCl pH 8, 100 mM NaCl, 1 mM beta-
mercaptoethanol, 1 µg/ml aprotinin and 1 µg/ml LP) by washing 2 to 3 times with at least 15 ml 
buffer. The supernatant was quickly transferred to the equilibrated Ni beads and incubated for 1 
hour at 4°C on rotation. The beads were harvested by centrifugation for 5 minutes at 4°C and 
1000 rpm and were washed for 2 to 3 times with 10 ml icecold wash buffer (50 mM tris.HCl pH 8, 
100 mM NaCl, 1 mM beta-mercaptoethanol, 1 µg/ml aprotinin and 1 µg/ml LP) for 5 minutes at 
4°C and 1000 rpm. The beads were transferred to a Sigma column. The bound His-TDG protein 
was eluted with 7 ml icecold His elution buffer.  
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14 x 0.5 ml fractions were collected and each fraction was tested for protein by spotting 1 µl on 
a nitrocellulose membrane and staining with Ponceau. The peak fractions were pooled and 
concentrated in a vivaspin2 column at 4000 rpm at 4°C. The concentrated protein solution was 
ultracentrifuged at 100 000g at 4°C for 10 min.  
The supernatant was applied to the ÄKTA S200 column which was already equilibrated in icecold 
transportbuffer complemented with (1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP). The flow 
rate was set on 0.5 ml/min and fractions of 0.5 ml were collected. The fractions were analysed 
via a chromatogram (a protein density profile) and via SDS-PAGE where 10 µl of each peak 
fraction were analysed on a 5-20% Gradient gel. Protein-containing fractions (7 to 9) were 
pooled and aliquots of 10 µl, 20 µl, 50 µl, 100 µl, 200 µl and 500 µl were prepared, frozen in 
liquid nitrogen and stored at -80°C. The protein concentration was estimated as 2 µg/µl= 28 µM 
with a reference protein on SDS-PAGE. 
6.8.7. CLONING OF MEF2A AND HSF1 
Myc epitope tagged human Hsf1  
Full-length hHSF1, cloned into the mammalian expression plasmid pcDNA3.1A (Invitrogen), was 
kindly provided by Lea Sistonen123. 
Hsf1 was cloned into pET23a by PCR-amplification of the Hsf1 ORF using using PCR with primers 
that incorporated the EcoRI and HindIII restriction sites.  
After digestion with EcoRI and HindIII restriction enzymes Hsf1 was ligated into pET23a in frame 
a His tag. 
 
GST-tagged Mef2A  
Full-length Mef2A, cloned pcDNA3.1 Myc His (A) ( Invitrogen), was kindly provided by Lea 
Sistonen 59.  
Mef2A was cloned into pGEX 6p.1 by performing a PCR using PCR primers with EcoRI and XhoI 
restriction sites. After PCR the amplicon was digested with the EcoRI and XhoI restriction 
enzymes and ligated into the likewise digested vector pGEX 6p.1 
6.8.8. EXPRESSION AND PURIFICATION OF HIS-HSF1 
One aliquot of BL21 gold competent bacteria was transformed with the plasmid pET23a His Hsf1. 
5 ml of LB complemented with kanamycin was added to the bacteria and the culture was grown 
for several hours at 37°C 200 rpm. In the afternoon the culture was transferred to 40 ml LB with 
kanamycin and grown overnight. The next day the culture was diluted in 1 litre LB/kanamycin 
and grown to an OD600 of 0.5 to 0.6. Then 1 ml aliquot of the culture was taken, centrifuged at 
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4000 rpm at room temperature, the LB was removed and the bacterial pellet was resuspended 
in 50 µl of 2x SDS-Laemmli buffer and boiled at 95°C for 5 minutes.  
Expression of His-Hsf1 was induced with IPTG at a final concentration of 1 mM. The culture was 
incubated at 16°C 200 rpm for 6 hours. Induced aliquots were taken every hour. After the 6 
hours bacteria were harvested by centrifugation at 4°C, at 4000 rpm and for 20 minutes in a 
Sorvall RC-5 Superspeed refrigerated centrifuge with a Sorvall GS-3 rotor. The pellet was 
resuspended in 15 ml (15ml/litre culture) of icecold lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 
10 mM imidazol, 0.1 mM PMSF, 1 mM beta-mercaptoethanol, 1 µg/ml aprotinin and 1 µg/ml 
LP). The pellet was frozen in liquid nitrogen and stored at -80°C. 
The next day the pellet was thawed and split into ultrazentrifuge tubes for Beckman rotor 
50.2Ti. 1 mg/ml lysozyme was added to the suspension and incubated for one hour on ice. Then 
it was ultracentrifuged for one hour in the ultracentrifuge Beckman (Optima) XL at 4°C at 100 
000g. In the meantime 3 ml ProBondTM resin (Ni-Beads) from Invitrogen (2-3 ml per litre culture) 
were equilibrated with lysis buffer (50 mM tris.HCl pH 8, 100 mM NaCl, 1 mM beta-
mercaptoethanol, 1 µg/ml aprotinin and 1 µg/ml LP) by washing 2 to 3 times with at least 15 ml 
buffer.  
The supernatant was quickly transferred to the equilibrated Ni beads and incubated for 1 hour at 
4°C while rotating. The beads were harvested by centrifugation for 5 minutes at 4°C and 1000 
rpm and washed for 2 to 3 times with 10 ml icecold wash buffer (50 mM tris.HCl pH 8, 100 mM 
NaCl, 1 mM beta-mercaptoethanol, 1 µg/ml aprotinin and 1 µg/ml LP). Then the beads were 
transferred to a column and the bound His-Hsf1 protein was eluted with 5 ml (10x 0.5 ml) 
icecold elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 1 mM beta-
mercaptoethanol, 1 µg/ml aprotinin and 1 µg/ml LP). Each of the collected fractions was tested 
for protein by spotting 1 µl on nitrocellulose membrane and staining with Ponceau.  
 
The peak fractions were pooled and applied to the ÄKTA S200 column, which was already 
equilibrated in icecold transportbuffer complemented with 1 mM DTT, 1 µg/ml aprotinin and 1 
µg/ml LP. The flow rate was set to 0.5 ml/min and fractions of 0.5 ml were collected. The 
fractions were analysed via a chromatogram (a protein density profile) and via SDS-PAGE where 
10 µl of each peak fraction were analysed on a 5-20 % gradient gel. Protein-containing fractions 
(12 to 16) were pooled and aliquots of 10 µl, 20 µl, 50 µl, 100 µl, 200 µl and 500 µl were 
prepared, frozen in liquid nitrogen and stored at -80°C. The protein concentration was estimated 
as 2 µg/µl= 25 µM with a reference protein on SDS-PAGE. 
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6.8.9. EXPRESSION AND PURIFICATION OF GST-MEF2A 
On the first day one aliquot of BL21 gold competent bacteria was transformed with the plasmid 
pGEX6p.1-Mef2A. 5 ml of LB complemented with ampicillin was added to the bacteria and the 
culture was grown during the day at 37°C 200 rpm. In the afternoon the culture was transferred 
to 40 ml LB with ampicillin and grown overnight. The next day the culture was diluted in 1 litre 
LB/ampicillin and grown to an OD600 of 0.5 to 0.6. Then 1 ml aliquot of the culture was taken, 
centrifuged at 4000 rpm at room temperature, the LB was removed and the bacterial pellet was 
resuspended in 50 µl of 2x SDS-Laemmli buffer and boiled at 95°C for 5 minutes.  
Expression of GST-Mef2A was induced with 1 mM IPTG. The culture was incubated at 16°C 200 
rpm for 6 hours. Induced aliquots were taken every hour. After the 6 hours bacteria were 
harvested via centrifugation at 4°C, at 4000 rpm and for 20 minutes in a Sorvall RC-5 Superspeed 
refrigerated centrifuge with a Sorvall GS-3 rotor. The pellet was resuspended in 15 ml (15ml/litre 
culture) of icecold lysis buffer (50 mM tris.HCl pH 8, 100 mM NaCl, 0.1 mM PMSF, 1 mM DTT, 1 
µg/ml aprotinin and 1 µg/ml LP). The pellet was frozen in liquid nitrogen and stored at -80°C. 
 
The next day the pellet was thawed and split into ultrazentrifuge tubes for Beckmann rotor 
50.2Ti. 1 mg/ml lysozyme was added to the suspension and incubated for one hour on ice 
followed by ultracentrifugation for one hour in the ultracentrifuge Beckman (Optima) XL at 4°C 
at 100 000g. In the meantime 2 ml Glutathione Sepharose 4B (GST-beads) from GE Healthcare 
(1-2 ml per litre culture) were equilibrated with lysis buffer (50 mM tris.HCl pH 8, 100 mM NaCl, 
1 mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP) by washing 2 to 3 times with at least 15 ml buffer. 
The supernatant was quickly transferred to the equilibrated GST beads and incubated for 1.5 
hours at 4°C on rotation. The beads were harvested by centrifugation for 5 minutes at 4°C and 
1000 rpm. The beads were washed for 2 to 3 times with 10 ml icecold lysis buffer for 5 minutes 
at 4°C and 1000 rpm and subsequently transferred to a column. The bound GST-Mef2A protein 
was eluted with 5 ml icecold elution buffer (50 mM Tris, 20 mM glutathione (reduced) pH 8, 1 
mM DTT, 1 µg/ml aprotinin and 1 µg/ml LP). 10 x 0.5 ml fractions were collected and each 
fraction was tested for protein by spotting 1 µl on nitrocellulose membrane and staining with 
Ponceau.  
 
The peak fractions were pooled and applied to the ÄKTA S200 column which was already 
equilibrated in icecold degased transportbuffer complemented with 1 mM DTT, 1 µg/ml 
aprotinin and 1 µg/ml LP. The flow rate was set on 0.5 ml/min and fractions of 0.5 ml were 
collected. The fractions were analysed via a chromatogram (a protein density profile) and via 
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SDS-PAGE where 10 µl of each peak fraction were analysed on a 5-20% gradient gel. Protein-
containing fractions (16 to 21) were pooled and aliquots of 10 µl, 20 µl, 50 µl, 100 µl, 200 µl and 
500 µl were prepared, frozen in liquid nitrogen and stored at -80°C. The protein concentration 
was estimated as 0.125 µg/µl= 1.6 µM with a reference protein on SDS-PAGE. 
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6.9. SUMO IN VITRO ASSAYS 
6.9.1. SUMOYLATION ACTIVITY COMPARISON OF TWO SEPARATELY PURIFIED 
UBC9 PREPARATIONS 
Table 8 Conditions of the sumoylation activity comparison of two seperatly purified Ubc9 purifications 
Enzymatic activity of Ubc9 Stock conc. Final conc. (Ubc9) Final conc. (S*Ubc9) Volume 
SUMO1 173 µM 4.4 µg (19 µM) 4.4 µg (19 µM) 2.2 µl 
E1 4.5 µM 150 ng (70 nM) 150 ng (70 nM) 0.3 µl 
"old"   Ubc9 No.1 111 µM 7 µM - 60 nM 0 2 µl or 
"new" Ubc9 No.2 111 µM 0 7 µM - 60 nM 2 µl 
E2-25K 60 µM 3.5 µg (6.6 µM) 3.5 µg (6.6 µM) 2.2 µl 
ATP 100 mM  5 mM 5 mM 1 µl 
Sumo Assay Buffer (SAB) 1 x x µl x µl 12.3 µl 
    20 µl 20 µl 20 µl 
Dilution steps of Ubc9 
7 µM/1.4 µM/280 nM/60 nM/0 
Incubation at 30 °C for 60 minutes 
6.9.2. SUMOYLATION OF E2-25K 
Table 9 Conditions of the SUMOylation assay of E2-25K 
Sumo assay Stock conc. Final conc. (Ubc9) Final conc. (S*Ubc9) Volume 
E2-25K 170 µM 2.2 µM 2.2 µM 0.134 µl 
HA-SUMO1 100 µM 4 µM 4 µM 0.8 µl 
E1 4.5 µM 100 nM 100 nM 0.44 µl 
Ubc9 111 µM 500 - 20 nM 0 2 µl or 
S*Ubc9 27 µM 0 500 - 20 nM 2 µl 
ATP 100 mM  5 mM 5 mM 1 µl 
MgCl2 2 M 100 mM 100 mM 1 µl 
Sumo Assay Buffer (SAB) 1 x x µl x µl 14.63 µl 
    20 µl 20 µl 20 µl 
Dilution steps of Ubc9/S*Ubc9 
500 nM/250 nM/100 nM/20 nM/0 
Incubation at 30 °C for 60 minutes 
6.9.3. SUMOYLATION OF RANGAP1 
Table 10 Conditions of the SUMO assay of RanGAP1 
Sumo assay Stock conc. Final conc. (Ubc9) Final conc. (S*Ubc9) Volume 
RanGAP1 11 µM 2.2 µM 2.2 µM 3.96 µl 
HA-SUMO1 100 µM 4 µM 4 µM 0.8 µl 
E1 4.5 µM 100 nM 100 nM 0.44 µl 
Ubc9 111 µM 50 - 0.4 nM 0 2 µl or 
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S*Ubc9 27 µM 0 50 - 0.4 nM 2 µl 
ATP 100 mM 5 mM 5 mM 1 µl 
MgCl2 2 M 100 mM 100 mM 1 µl 
Sumo Assay Buffer (SAB) 1 x x µl x µl 10.8 µl 
    20 µl 20 µl 20 µl 
  Dilution steps of Ubc9/S*Ubc9 
50 nM/10 nM/2 nM/0.4 nM/0 
Incubation at 30 °C for 30 minutes 
6.9.4. SUMOYLATION OF TDG 
Table 11 Conditions of the SUMO assay of His-TDG 
Sumo assay Stock conc. Final conc. (Ubc9) Final conc. (S*Ubc9) Volume 
His-TDG 28 µM 500 ng (357 nM) 500 ng (357 nM) 0.25 µl 
HA-SUMO1 100 µM 4 µM 4 µM 0.8 µl 
E1 4.5 µM 100 nM 100 nM 0.44 µl 
Ubc9 111 µM 500 - 20 nM 0 2 µl or 
S*Ubc9 27 µM 0 500 - 20 nM 2 µl 
ATP 100 mM  5 mM 5 mM 1 µl 
MgCl2 2 M 100 mM 100 mM 1 µl 
Sumo Assay Buffer (SAB) 1 x x µl x µl 14.51 µl 
    20 µl 20 µl 20 µl 
Dilution steps of Ubc9/S*Ubc9 
500 nM/250 nM/100 nM/20 nM/0 
Incubation at 30 °C for 60 minutes 
 
6.9.5. SUMOYLATION OF DAXX 
Table 12 Conditions of the SUMO assay of GST-DAXX 
Sumo assay Stock conc. Final conc. (Ubc9) Final conc. (S*Ubc9) Volume 
GST-DAXX 40 µM 500 ng (625 nM) 500 ng (625 nM) 0.25 µl 
HA-SUMO1 100 µM 4 µM 4 µM 0.8 µl 
E1 4.5 µM 100 nM 100 nM 0.44 µl 
Ubc9 111 µM 1 µM - 100 nM 0 2 µl or 
S*Ubc9 27 µM 0 1 µM - 100 nM 2 µl 
ATP 100 mM  5 mM 5 mM 1 µl 
MgCl2 2 M 100 mM 100 mM 1 µl 
Sumo Assay Buffer (SAB) 1 x x µl x µl 14.51 µl 
    20 µl 20 µl 20 µl 
Dilution steps of Ubc9/S*Ubc9 
1 µM/500 nM/250 nM/100 nM/0 
Incubation at 30 °C for 60 minutes 
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6.9.6. SUMOYLATION OF HSF1 
Table 13 Conditions of the SUMO assay of the substrate His-Hsf1 
Sumo assay Stock conc. Final conc. (Ubc9) Final conc. (S*Ubc9) Volume 
His-Hsf1 25 µM 500 ng (333 nM) 500 ng (333 nM) 1 µl 
HA-SUMO1 100 µM 4 µM 4 µM 0.8 µl 
E1 4.5 µM 100 nM 100 nM 0.44 µl 
Ubc9 111 µM 1 µM - 100 nM 0 2 µl or 
S*Ubc9 27 µM 0 1 µM - 100 nM 2 µl 
ATP 100 mM  5 mM 5 mM 1 µl 
MgCl2 2 M 100 mM 100 mM 1 µl 
Sumo Assay Buffer (SAB) 1 x x µl x µl 13.76 µl 
    20 µl 20 µl 20 µl 
Dilution steps of Ubc9/S*Ubc9 
1 µM/500 nM/250 nM/100 nM/0 
Incubation at 30 °C for 60 minutes 
6.9.7. SUMOYLATION OF MEF2A 
Table 14 Conditions of the SUMO assay of the substrate GST-Mef2A 
Sumo assay Stock conc. Final conc. (Ubc9) Final conc. (S*Ubc9) Volume 
GST-Mef2A 1.6 µM 1 µg (641 nM) 1 µg (641 nM) 8 µl 
HA-SUMO1 100 µM 4 µM 4 µM 0.8 µl 
E1 4.5 µM 100 nM 100 nM 0.44 µl 
Ubc9 111 µM 1 µM - 100 nM 0 2 µl or 
S*Ubc9 27 µM 0 1 µM - 100 nM 2 µl 
ATP 100 mM  5 mM 5 mM 1 µl 
MgCl2 2 M 100 mM 100 mM 1 µl 
Sumo Assay Buffer (SAB) 1 x x µl x µl 6.76 µl 
    20 µl 20 µl 20 µl 
Dilution steps of Ubc9/S*Ubc9 
1 µM/500 nM/250 nM/100 nM/0 
Incubation at 30 °C for 60 minutes 
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6.10. PROTO ARRAY 
 
Purified enzymes were sent to Invitrogen ProtoArray Service at – 20°C, the α-HA.11 antibody 
from Covance was sent at 4 °C. The probing and detection of the ProtoArray was performed by 
the ProtoArray Service. 
E1 was used as a 4.5 µM solution and diluted to a final concentration of 100 nM in all assays. 
Ubc9 and S*Ubc9 were diluted from a 111 µM and 27 µM stock solution to either 100 nM or 500 
nM working concentration (Table 16). HA-SUMO was diluted from a 100 µM solution to a final 
concentration of 4 µM. Energy regeneration solution (Boston Biochem) was used at a final 
concentration of 1X.  
 
Table 15 ProtoArray Assay conditions 
  Stock 100 nM 
Ubc9 
500 nM 
Ubc9 
100 nM 
S*Ubc9 
500 nM 
S*Ubc9 
Sumo/E1 
only 
Neg. 
control 
HA-SUMO1  
(4 µM) 
100 µM 4 µl 4 µl 4 µl 4 µl 4 µl  - 
E1 (100 nM) 4.5 µM 2.22 µl 2.22 µl 2.22 µl 2.22 µl 2.22 µl  - 
Ubc9 111 µM 0.09 µl 0.45 µl - -  -  - 
S*Ubc9 27 µM  -  - 0.37 µl 1.85 µl  -  - 
ATP (5 mM) 100 nM 5 µl 5 µl 5 µl 5 µl 5 µl  - 
Sumo Assay 
Buffer 
1 x 88.69 μl 88.33 μl 88.41 μl 86.93 μl 88.78 μl 100 µl 
  100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
 
The slides were blocked in 4-well QuadriPERM trays (Greiner) with 5 ml blocking buffer (50mM 
HEPES pH 7.5, 200mM NaCl, 0.08% Triton X-100, 25% glycerol, 20mM reduced glutathione, 1mM 
DTT and 1% BSA) for 60 minutes at 4°C on a shaker at 50 rpm (circular shaking).  
Reactions were prepared in Sumo Assay Buffer and incubated at 30 °C for 10 minutes. Then 120 
µl of each reaction mixture was applied to the slides and overlayed with a Lifterslip (Erie 
Scientific) taking care not to produce bubbles. Slides were incubated at 30°C for 60 minutes, 
followed by three 5 minute washes with 5 ml assay buffer from Invitrogen (50 mM tris pH 7.5, 50 
mM NaCl, 5 mM MgSO4, 0.1 % Tween 20 and 1 % BSA).  
Then the arrays were washed with three 5 minute washes using 5 ml 0.5 % SDS, three 5 minute 
washes with 5 ml assay buffer and one 5 minute wash with 5 ml PBST (1X PBS, 0.1% Tween-20, 
1X Synthetic Block). Arrays were then incubated with assay buffer containing 1:1500 dilution of 
mouse anti-HA antibody (end concentration of 3.3 – 4.6 µg/ml) for 90 minutes at 4 °C and then 
washed four times with PBST. Arrays were then incubated with 5 ml of the secondary detection 
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reagent AlexaFluor 647-conjugated rabbit anit-mouse IgG (Invitrogen, end concentration of 1 
µg/ml) in assay buffer) at 4 °C for 90 minutes and then washed 5 times with PBST.  
All arrays were quickly rinsed in water to remove residual salts. Arrays were dried by 
centrifugation at 1000 rpm for 2 minutes in a table top centrifuge equipped with a plate rotor. 
The arrays were then scanned using an Axon GenePix 4000B fluorescent microarray scanner at 
668nm. Data was acquired with GenePix 6.0 software and processed in ProtoArray Prospector. 
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ABBREVATIONS 
 
ADP    Adenosine di-phosphate 
Aos    activation of Smt3p 
AP    aprotinin 
ATP    Adenosine tri-phosphate 
Daxx    Death domain-associated protein 6 
DTT    Dithiothreitol  
FPLC    fast protein liquid chromatography 
GST    glutathione-S-transferase 
HA    hemagglutinin 
HIS    poly-histidine 
HSF    Heat Shock Factor 
IPTG    Isopropyl-β-D-thiogalactopyranosid 
LP    leupeptin / pepstatin 
MEF2A    Myocyte Enhancement Factor 2A 
NDSM    negative charged dependent SUMO motif 
OD600    Optical Density at the wavelength 600 nm 
PDSM    phosphorylation dependent SUMO motif 
PI    protease inhibitors 
PIAS    protein inhibitor of activated STAT 
PML    promyelocytic leukemia  
RanGAP   Ran GTP activating protein 
S*    modified with SUMO 
SDS-PAGE   sodium dodecylsulfate polyacrylamide gel electrophoresis 
SIM    SUMO interaction motif 
SUMO    small ubiquitin-related modifier 
TDG    thymine DNA glycosylase 
Uba    Ubiquitin activating 
Ubc    Ubiquitin conjugating 
*    Conjugated 
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